

BIOMET INC
Form 10-Q
April 13, 2012

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended February 29, 2012.

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____
Commission File Number 000-54505

Commission File Number 001-15601

LVB ACQUISITION, INC.
BIOMET, INC.

Edgar Filing: BIOMET INC - Form 10-Q

(Exact name of registrant as specified in its charter)

Delaware

26-0499682

Indiana

35-1418342

(State or other jurisdiction of

(I.R.S. Employer

incorporation or organization)

Identification No.)

56 East Bell Drive, Warsaw, Indiana

46582

(Address of principal executive offices)

(Zip Code)

(574) 267-6639

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

LVB ACQUISITION, INC. Yes No

BIOMET, INC. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

LVB ACQUISITION, INC. Yes No

BIOMET, INC. Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

LVB ACQUISITION, INC.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

BIOMET, INC.

Edgar Filing: BIOMET INC - Form 10-Q

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

LVB ACQUISITION, INC. Yes No

BIOMET, INC. Yes No

The number of shares of the registrants' common stock outstanding as of March 31, 2012:

LVB ACQUISITION, INC. 552,331,876 shares of common stock

BIOMET, INC. 1,000 shares of common stock

TABLE OF CONTENTS

	Page
Part I. <u>Financial Information</u>	
Item 1. <u>Condensed Consolidated Financial Statements (Unaudited):</u>	
<u>LVB Acquisition, Inc. and Subsidiaries Condensed Consolidated Balance Sheets as of February 29, 2012 and May 31, 2011</u>	4
<u>LVB Acquisition, Inc. and Subsidiaries Condensed Consolidated Statements of Operations for the Three and Nine Months Ended February 29, 2012 and February 28, 2011</u>	5
<u>LVB Acquisition, Inc. and Subsidiaries Condensed Consolidated Statements of Cash Flows for the Nine Months Ended February 29, 2012 and February 28, 2011</u>	6
<u>Biomet, Inc. and Subsidiaries Condensed Consolidated Balance Sheets as of February 29, 2012 and May 31, 2011</u>	7
<u>Biomet, Inc. and Subsidiaries Condensed Consolidated Statements of Operations for the Three and Nine Months Ended February 29, 2012 and February 28, 2011</u>	8
<u>Biomet, Inc. and Subsidiaries Condensed Consolidated Statements of Cash Flows for the Nine Months Ended February 29, 2012 and February 28, 2011</u>	9
<u>Notes to Condensed Consolidated Financial Statements</u>	10
Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	31
Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	44
Item 4. <u>Controls and Procedures</u>	44
Part II. <u>Other Information</u>	
There is no information required to be reported under any items except those indicated below.	
Item 1. <u>Legal Proceedings</u>	44
Item 1A. <u>Risk Factors</u>	44
Item 6. <u>Exhibits</u>	47

PART I. FINANCIAL INFORMATION

Explanatory Note

This Form 10-Q is a combined quarterly report being filed separately by two registrants: LVB Acquisition, Inc. (LVB) and Biomet, Inc. Unless the context indicates otherwise, any reference in this report to the Company, we, us and our refer to LVB, Biomet, Inc. and its subsidiaries. Each registrant hereto is filing on its own behalf all of the information contained in this quarterly report that relates to such registrant. Each registrant hereto is not filing any information that does not relate to such registrant, and therefore makes no representation as to any such information.

Item 1. Condensed Consolidated Financial Statements.
LVB Acquisition, Inc. and Subsidiaries Condensed Consolidated Balance Sheets.

(in millions, except shares)

	(Unaudited) February 29, 2012	May 31, 2011
Assets		
Current assets:		
Cash and cash equivalents	\$ 496.0	\$ 327.8
Accounts receivable, less allowance for doubtful receivables of \$38.5 (\$38.2 at May 31, 2011)	507.4	480.1
Investments	3.8	41.4
Income tax receivable	3.1	5.4
Inventories, net	555.8	582.5
Deferred income taxes	72.3	71.5
Prepaid expenses and other	111.4	109.7
Total current assets	1,749.8	1,618.4
Property, plant and equipment, net	598.9	638.4
Investments	14.3	33.1
Intangible assets, net	4,275.0	4,534.4
Goodwill	4,445.4	4,470.1
Other assets	55.2	62.6
Total assets	\$ 11,138.6	\$ 11,357.0
Liabilities & Shareholders' Equity		
Current liabilities:		
Current portion of long-term debt	\$ 36.6	\$ 37.4
Accounts payable	85.2	91.1
Accrued interest	125.8	64.1
Accrued wages and commissions	98.1	105.0
Other accrued expenses	221.1	241.8
Total current liabilities	566.8	539.4
Long-term liabilities:		
Long-term debt, net of current portion	5,883.5	5,982.9
Deferred income taxes	1,370.4	1,487.6
Other long-term liabilities	206.8	172.0
Total liabilities	8,027.5	8,181.9
Commitments and contingencies		
Shareholders' equity:		
Common stock, par value \$0.01 per share; 740,000,000 shares authorized; 552,331,876 and 552,531,316 shares issued and outstanding	5.5	5.5
Contributed and additional paid-in capital	5,619.6	5,608.6
Accumulated deficit	(2,680.5)	(2,610.8)
Accumulated other comprehensive income	166.5	171.8
Total shareholders' equity	3,111.1	3,175.1
Total liabilities and shareholders' equity	\$ 11,138.6	\$ 11,357.0

The accompanying notes are an integral part of the condensed consolidated financial statements.

LVB Acquisition, Inc. and Subsidiaries Condensed Consolidated Statements of Operations.*(in millions)*

	(Unaudited) Three Months Ended		(Unaudited) Nine Months Ended	
	February 29, 2012	February 28, 2011	February 29, 2012	February 28, 2011
Net sales	\$ 708.9	\$ 678.0	\$ 2,098.6	\$ 2,017.0
Cost of sales	219.7	208.1	669.9	609.6
Gross profit	489.2	469.9	1,428.7	1,407.4
Selling, general and administrative expense	268.4	252.9	800.9	765.4
Research and development expense	30.1	28.8	93.2	88.3
Amortization	82.6	93.3	250.0	283.3
Operating income	108.1	94.9	284.6	270.4
Interest expense	117.2	124.0	363.4	373.7
Other (income) expense	(2.8)	(3.0)	9.3	(8.7)
Other expense, net	114.4	121.0	372.7	365.0
Loss before income taxes	(6.3)	(26.1)	(88.1)	(94.6)
Provision (benefit) from income taxes	10.2	(14.5)	(18.4)	(57.6)
Net loss	\$ (16.5)	\$ (11.6)	\$ (69.7)	\$ (37.0)

The accompanying notes are an integral part of the condensed consolidated financial statements.

LVB Acquisition, Inc. and Subsidiaries Condensed Consolidated Statements of Cash Flows.

(in millions)

	(Unaudited)	
	Nine Months Ended	
	February 29, 2012	February 28, 2011
Cash flows provided by (used in) operating activities:		
Net loss	\$ (69.7)	\$ (37.0)
Adjustments to reconcile net loss to net cash provided by operating activities:		
Depreciation and amortization	388.0	417.5
Amortization of deferred financing costs	8.3	8.4
Stock-based compensation expense	12.2	14.6
Recovery of doubtful accounts receivable	(2.6)	(3.9)
Realized gain on investments	(1.9)	(4.9)
Loss on impairment of investments	19.3	
Property, plant and equipment impairment charge	0.4	0.6
Provision for inventory obsolescence	9.5	11.8
Deferred income taxes	(120.7)	(98.4)
Loss on extinguishment of debt		1.2
Other	(2.0)	(12.1)
Changes in operating assets and liabilities:		
Accounts receivable	(38.4)	11.7
Inventories	0.1	(65.0)
Prepaid expenses	(1.2)	(8.4)
Accounts payable	(4.2)	(7.2)
Income taxes	19.1	14.0
Accrued interest	61.7	61.1
Accrued expenses and other	13.4	(0.8)
Net cash provided by operating activities	291.3	303.2
Cash flows provided by (used in) investing activities:		
Proceeds from sales/maturities of investments	42.0	14.6
Purchases of investments	(0.3)	(44.3)
Proceeds from sale of property and equipment	13.7	6.1
Capital expenditures	(122.7)	(133.9)
Acquisitions, net of cash acquired	(14.4)	(18.3)
Net cash used in investing activities	(81.7)	(175.8)
Cash flows provided by (used in) financing activities:		
Debt:		
Payments under European facilities	(1.1)	(1.5)
Proceeds under European facilities		0.2
Payments under senior secured credit facilities	(26.6)	(25.9)
Repurchase of senior notes		(11.2)
Equity:		
Repurchase of LVB Acquisition, Inc. shares	(1.2)	(1.2)
Net cash used in financing activities	(28.9)	(39.6)
Effect of exchange rate changes on cash	(12.5)	10.8
Increase in cash and cash equivalents	168.2	98.6
Cash and cash equivalents, beginning of period	327.8	189.1
Cash and cash equivalents, end of period	\$ 496.0	\$ 287.7

Edgar Filing: BIOMET INC - Form 10-Q

Supplemental disclosures of cash flow information:

Cash paid during the period for:

Interest	\$ 294.0	\$ 304.4
Income taxes	\$ 76.9	\$ 28.2

The accompanying notes are an integral part of the condensed consolidated financial statements.

Biomet, Inc. and Subsidiaries Condensed Consolidated Balance Sheets.*(in millions, except shares)*

	(Unaudited) February 29, 2012	May 31, 2011
Assets		
Current assets:		
Cash and cash equivalents	\$ 496.0	\$ 327.8
Accounts receivable, less allowance for doubtful receivables of \$38.5 (\$38.2 at May 31, 2011)	507.4	480.1
Investments	3.8	41.4
Income tax receivable	3.1	5.4
Inventories, net	555.8	582.5
Deferred income taxes	72.3	71.5
Prepaid expenses and other	111.4	109.7
Total current assets	1,749.8	1,618.4
Property, plant and equipment, net	598.9	638.4
Investments	14.3	33.1
Intangible assets, net	4,275.0	4,534.4
Goodwill	4,445.4	4,470.1
Other assets	55.2	62.6
Total assets	\$ 11,138.6	\$ 11,357.0
Liabilities & Shareholder's Equity		
Current liabilities:		
Current portion of long-term debt	\$ 36.6	\$ 37.4
Accounts payable	85.2	91.1
Accrued interest	125.8	64.1
Accrued wages and commissions	98.1	105.0
Other accrued expenses	221.1	241.8
Total current liabilities	566.8	539.4
Long-term liabilities:		
Long-term debt, net of current portion	5,883.5	5,982.9
Deferred income taxes	1,370.4	1,487.6
Other long-term liabilities	206.8	172.0
Total liabilities	8,027.5	8,181.9
Commitments and contingencies		
Shareholder's equity:		
Common stock, par value \$0.00 per share; 1,000 shares authorized; 1,000 shares issued and outstanding		
Contributed and additional paid-in capital	5,625.1	5,614.1
Accumulated deficit	(2,680.5)	(2,610.8)
Accumulated other comprehensive income	166.5	171.8
Total shareholder's equity	3,111.1	3,175.1
Total liabilities and shareholder's equity	\$ 11,138.6	\$ 11,357.0

The accompanying notes are an integral part of the condensed consolidated financial statements.

Biomet, Inc. and Subsidiaries Condensed Consolidated Statements of Operations.*(in millions)*

	(Unaudited)		(Unaudited)	
	Three Months Ended February 29, 2012	February 28, 2011	Nine Months Ended February 29, 2012	February 28, 2011
Net sales	\$ 708.9	\$ 678.0	\$ 2,098.6	\$ 2,017.0
Cost of sales	219.7	208.1	669.9	609.6
Gross profit	489.2	469.9	1,428.7	1,407.4
Selling, general and administrative expense	268.4	252.9	800.9	765.4
Research and development expense	30.1	28.8	93.2	88.3
Amortization	82.6	93.3	250.0	283.3
Operating income	108.1	94.9	284.6	270.4
Interest expense	117.2	124.0	363.4	373.7
Other (income) expense	(2.8)	(3.0)	9.3	(8.7)
Other expense, net	114.4	121.0	372.7	365.0
Loss before income taxes	(6.3)	(26.1)	(88.1)	(94.6)
Provision (benefit) from income taxes	10.2	(14.5)	(18.4)	(57.6)
Net loss	\$ (16.5)	\$ (11.6)	\$ (69.7)	\$ (37.0)

The accompanying notes are an integral part of the condensed consolidated financial statements.

Biomet, Inc. and Subsidiaries Condensed Consolidated Statements of Cash Flows.*(in millions)*

	(Unaudited)	
	Nine Months Ended	
	February 29, 2012	February 28, 2011
Cash flows provided by (used in) operating activities:		
Net loss	\$ (69.7)	\$ (37.0)
Adjustments to reconcile net loss to net cash provided by operating activities:		
Depreciation and amortization	388.0	417.5
Amortization of deferred financing costs	8.3	8.4
Stock-based compensation expense	12.2	14.6
Recovery of doubtful accounts receivable	(2.6)	(3.9)
Realized gain on investments	(1.9)	(4.9)
Loss on impairment of investments	19.3	
Property, plant and equipment impairment charge	0.4	0.6
Provision for inventory obsolescence	9.5	11.8
Deferred income taxes	(120.7)	(98.4)
Loss on extinguishment of debt		1.2
Other	(2.0)	(12.1)
Changes in operating assets and liabilities:		
Accounts receivable	(38.4)	11.7
Inventories	0.1	(65.0)
Prepaid expenses	(1.2)	(8.4)
Accounts payable	(4.2)	(7.2)
Income taxes	19.1	14.0
Accrued interest	61.7	61.1
Accrued expenses and other	13.4	(0.8)
Net cash provided by operating activities	291.3	303.2
Cash flows provided by (used in) investing activities:		
Proceeds from sales/maturities of investments	42.0	14.6
Purchases of investments	(0.3)	(44.3)
Proceeds from sale of property and equipment	13.7	6.1
Capital expenditures	(122.7)	(133.9)
Acquisitions, net of cash acquired	(14.4)	(18.3)
Net cash used in investing activities	(81.7)	(175.8)
Cash flows provided by (used in) financing activities:		
Debt:		
Payments under European facilities	(1.1)	(1.5)
Proceeds under European facilities		0.2
Payments under senior secured credit facilities	(26.6)	(25.9)
Repurchase of senior notes		(11.2)
Equity:		
Repurchase of LVB Acquisition, Inc. shares	(1.2)	(1.2)
Net cash used in financing activities	(28.9)	(39.6)
Effect of exchange rate changes on cash	(12.5)	10.8
Increase in cash and cash equivalents	168.2	98.6
Cash and cash equivalents, beginning of period	327.8	189.1
Cash and cash equivalents, end of period	\$ 496.0	\$ 287.7

Edgar Filing: BIOMET INC - Form 10-Q

Supplemental disclosures of cash flow information:

Cash paid during the period for:

Interest	\$ 294.0	\$ 304.4
Income taxes	\$ 76.9	\$ 28.2

The accompanying notes are an integral part of the condensed consolidated financial statements.

LVB ACQUISITION, INC.**BIOMET, INC.****Notes to Condensed Consolidated Financial Statements (Unaudited)****Note 1 Basis of Presentation.**

The accompanying unaudited condensed consolidated financial statements include the accounts of LVB Acquisition, Inc. (LVB and Parent) and Biomet, Inc. and its subsidiaries (individually and collectively with its subsidiaries referred to as Biomet , and together with LVB, the Company , we , us , or our). Biomet is a wholly owned subsidiary of LVB. LVB has no other operations beyond its ownership of Biomet. Intercompany accounts and transactions have been eliminated in consolidation.

The unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for condensed financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X. As a result, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the financial condition, results of operations and cash flows for the periods presented have been included. Operating results for the three and nine month periods ended February 29, 2012 are not necessarily indicative of the results that may be expected for the fiscal year ending May 31, 2012. For further information, including the Company s significant accounting policies, refer to the audited consolidated financial statements and notes thereto included in Biomet, Inc. s Annual Report on Form 10-K for the fiscal year ended May 31, 2011 (the 2011 10-K) and LVB s Registration Statement on Form 10/A filed with the Securities and Exchange Commission (SEC) on December 21, 2011 (the Form 10/A).

The May 31, 2011 balances have been derived from the audited financial statements included in (1) Biomet s 2011 Form 10-K and (2) LVB Acquisition, Inc. s Form 10/A.

Recent Accounting Pronouncements There are no recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on the Company s financial position, results of operations or cash flows.

Note 2 Inventories.

Inventories are stated at the lower of cost or market, with cost determined under the first-in, first-out method. The Company reviews inventory on hand and writes down excess and slow-moving inventory based on an assessment of future demand and historical experience. Inventories consisted of the following:

<i>(in millions)</i>	February 29, 2012	May 31, 2011
Raw materials	\$ 80.3	\$ 85.0
Work-in-process	42.3	44.8
Finished goods	433.2	452.7
Inventories, net	\$ 555.8	\$ 582.5

Note 3 Property, Plant and Equipment.

Property, plant and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of 3 to 30 years. Depreciation of instruments is included within cost of sales. Related maintenance and repairs are expensed as incurred.

The Company reviews property, plant and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows relating to the asset, or asset group, are less than its carrying value, with the amount of the loss equal to the excess of carrying value of the asset, or asset group, over the estimated fair value.

Note 3 Property, Plant and Equipment, Continued.

Property, plant and equipment consisted of the following:

<i>(in millions)</i>	February 29, 2012	May 31, 2011
Land and land improvements	\$ 40.7	\$ 43.5
Buildings and leasehold improvements	90.4	110.9
Machinery and equipment	339.3	328.6
Instruments	638.5	573.0
Construction in progress	30.8	30.8
Total property, plant and equipment	1,139.7	1,086.8
Accumulated depreciation	(540.8)	(448.4)
Total property, plant and equipment, net	\$ 598.9	\$ 638.4

Note 4 Investments.

At February 29, 2012, the Company's investment securities were classified as follows:

<i>(in millions)</i>	Amortized Cost	Unrealized Gains	Unrealized Losses	Fair Value
Available-for-sale:				
Equity securities	\$ 0.5	\$ 0.1	\$ (0.2)	\$ 0.4
Money market funds	9.5			9.5
Greek bonds	7.8			7.8
Total available-for-sale investments	\$ 17.8	\$ 0.1	\$ (0.2)	\$ 17.7

	Amortized Cost	Realized Gains	Realized Losses	Fair Value
Trading:				
Equity securities	\$ 0.4	\$	\$	\$ 0.4
Total trading investments	\$ 0.4	\$	\$	\$ 0.4

At May 31, 2011, the Company's investment securities were classified as follows:

<i>(in millions)</i>	Amortized Cost	Unrealized Gains	Unrealized Losses	Fair Value
Available-for-sale:				
Equity securities	\$ 0.5	\$ 0.1	\$ (0.2)	\$ 0.4
Money market funds	9.5			9.5
Time deposit	33.1			33.1
Greek bonds	35.6		(4.5)	31.1
Other investments	0.3			0.3

Edgar Filing: BIOMET INC - Form 10-Q

Total available-for-sale investments	\$	79.0	\$	0.1	\$	(4.7)	\$	74.4
--------------------------------------	----	------	----	-----	----	-------	----	------

		Amortized Cost		Realized Gains		Realized Losses		Fair Value
Trading:								
Equity securities	\$	0.1	\$		\$			\$ 0.1
Total trading investments	\$	0.1	\$		\$			\$ 0.1

The Company recorded proceeds on the sales/maturities of investments of \$8.3 million and \$42.0 million for the three and nine months ended February 29, 2012, respectively, and \$2.9 million and \$14.6 million for the three and nine months ended February 28, 2011, respectively. The Company recorded a realized gain of \$1.9 million for both the three and nine months ended February 29, 2012 and \$2.3 million and \$4.9 million for the three and nine months ended February 28, 2011, respectively, that was included in other (income) expense.

The Company received \$45.5 million face value zero coupon bonds in December 2010 from the Greek government as payment for an outstanding accounts receivable balance from calendar years 2007-2009 related to certain government

Note 4 Investments, Continued.

sponsored institutions in a non-cash transaction. Upon receipt, the bonds had a fair value of \$33.8 million, with maturity dates of one to three years. The bonds are designated as available-for-sale securities. The Company recorded realized losses of \$2.8 million and \$19.3 million on the Greek bonds related to other-than-temporary impairment for the three and nine months ended February 29, 2012, respectively, which is included in other (income) expense with no other-than-temporary impairment recorded for the three and nine months ended February 28, 2011. The one year bonds matured in December 2011 and the Company received the full par value of approximately \$8.4 million. On March 9, 2012 the Greek government finalized the private sector involvement in the Greek debt restructuring. All holders of Greek government bonds are required to exchange the existing bonds to new bonds. The new bonds will have maturities ranging from 1 to 30 years with the face value reduced by 53%. At February 29, 2012 the face value of the bonds was \$36.4 million.

The Company reviews impairments to investment securities quarterly to determine if the impairment is temporary or other-than-temporary. The Company reviews several factors to determine whether losses are other-than-temporary, including but not limited to (1) the length of time each security was in an unrealized loss position, (2) the extent to which fair value was less than cost, (3) the financial condition and near-term prospects of the issuer, and (4) the Company's intent and ability to hold each security for a period of time sufficient to allow for any anticipated recovery in fair value.

Note 5 Goodwill and Other Intangible Assets.

The balance of goodwill at February 29, 2012 and May 31, 2011 was \$4,445.4 million and \$4,470.1 million, respectively. The change in goodwill reflects foreign currency fluctuations, primarily the weakening of the euro against the U.S. dollar.

The Company uses an accelerated method for amortizing customer relationship intangibles as the value for those relationships is greater at the beginning of their life. The accelerated method was calculated using historical customer attrition rates. The remaining finite-lived intangibles are amortized on a straight line basis. The decrease in the net intangible asset balance from \$4,470.1 at May 31, 2011 to \$4,275.0 at February 29, 2012 is primarily due to amortization and the weakening of the euro against the U.S. dollar.

The Company operates in one reportable segment and evaluates goodwill for impairment at the reporting unit level. Effective September 1, 2011, in connection with the Company's global reorganization, the Company made changes to its reporting unit structure. The reorganization eliminated three reporting units (U.S. Orthopedics, Sports Medicine and Biologics) and established a new reporting unit (U.S. Reconstructive). The Company formerly had eight, and now has six, identified reporting units for the purpose of testing goodwill for impairment. The reporting units are based on the Company's current administrative organizational structure and the availability of discrete financial information.

The Company performs its annual assessment for impairment at March 31 for all reporting units and tests these balances more frequently if indicators are present or changes in circumstances suggest that impairment may exist. The estimates and assumptions underlying the fair value calculations used in the Company's annual impairment tests are uncertain by their nature and can vary significantly from actual results. Factors that management must estimate include, but are not limited to, industry and market conditions, sales volume and pricing, raw material costs, capital expenditures, working capital changes, cost of capital, and tax rates. These factors are especially difficult to predict when global financial markets are volatile. The estimates and assumptions used in its impairment tests are consistent with those the Company uses in its internal planning. These estimates and assumptions may change from period to period. If the Company uses different estimates and assumptions in the future, impairment charges may occur and could be material.

In performing the test on goodwill, the Company utilizes the two-step approach prescribed under guidance issued by the Financial Accounting Standards Board (FASB). The first step under this guidance requires a comparison of the carrying value of the reporting units, of which the Company has identified six in total, to the fair value of these reporting units. The Company uses the income approach to determine the fair value of each reporting unit. The approach calculates fair value by estimating the after-tax cash flows attributable to a reporting unit and then discounting these after-tax cash flows to a present value using a risk-adjusted discount rate. To derive the carrying value of the Company's reporting units, the Company assigns goodwill to the reporting units. In addition, for purposes of performing the goodwill test, certain corporate assets and liabilities are allocated to the individual reporting units. Assets and liabilities include an allocation of those corporate assets that relate to a reporting unit's operations, and would be considered in determining fair value. The Company allocates assets and liabilities that are not directly related to a specific reporting unit, but from which the reporting unit benefits, based primarily on the respective revenue contribution of each reporting unit. If the carrying value of a reporting unit exceeds its fair value, the Company performs the second step of the goodwill impairment test to measure the amount of impairment loss, if any.

The second step of the goodwill impairment test compares the implied fair value of a reporting unit's goodwill to its carrying value. If the Company is unable to complete the second step of the test prior to the issuance of its financial statements and an impairment loss is probable and could be reasonably estimated, the Company recognizes its best estimate of the loss in its current period financial statements and discloses that

Edgar Filing: BIOMET INC - Form 10-Q

amount as an estimate. The Company then recognizes any adjustment to that estimate in subsequent reporting periods, once the Company has finalized the second step of the impairment test.

Note 5 Goodwill and Other Intangible Assets, Continued.

The Company determines the fair value of indefinite lived intangible assets, primarily tradenames, using the relief-from-royalty method, an income based approach. The approach calculates fair value by estimating the after-tax cash flows attributable to the asset and then discounting these after-tax cash flows to a present value using a risk-adjusted discount rate. The calculated fair value is compared to the carrying value to determine if any impairment exists.

If events or circumstances change, a determination is made by management to ascertain whether certain finite-lived intangibles have been impaired based on the sum of expected future undiscounted cash flows from operating activities. If the estimated net cash flows are less than the carrying amount of such assets, an impairment loss is recognized in an amount necessary to write down the assets to fair value as determined from expected future discounted cash flows.

As of February 29, 2012, the Company concluded that certain indicators were present that suggested impairment may exist for its Dental Reconstructive reporting unit's goodwill and intangibles. The Dental Reconstructive reporting unit had goodwill of \$433.3 million and intangibles of \$458.6 million at February 29, 2012. The indicators of potential impairment in the Company's Dental Reconstructive reporting unit include evidence of declining industry market growth rates in certain European and Asia Pacific markets and unfavorable margin trends resulting from change in product mix.

The impact of these recent items resulted in management initiating a preliminary step one test of goodwill and intangibles for the Dental reporting unit at February 29, 2012. However, the preliminary result of this interim test of impairment for the Dental Reconstructive reporting unit's goodwill and intangibles was inconclusive. The Company is currently completing its annual budget and strategic planning process and is continuing to evaluate overall long-term growth rates, industry information, and other valuation assumptions. The Company will finalize the February 29, 2012 impairment tests during its fourth quarter of fiscal 2012.

The Company has identified other reporting units with a material amount of goodwill that are at a higher risk of potential failure of step one of the goodwill impairment test in the future. These reporting units include the U.S. Reconstructive reporting unit (\$2,971.9 million of goodwill), the Spine and Bone Healing reporting unit (\$163.8 million of goodwill), the International reporting unit (\$569.4 million of goodwill) and the Europe reporting unit (\$241.7 million of goodwill). The level of excess fair value over carrying value for each of these higher risk reporting units is less than 10%.

Intangible assets consisted of the following at February 29, 2012 and May 31, 2011:

<i>(in millions)</i>	February 29, 2012			May 31, 2011					
	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	Gross Carrying Amount	Impairment Charge	New Carrying Amount	Accumulated Amortization	Impairment Charge	Net Carrying Amount
Core technology	\$ 1,850.0	\$ (435.3)	\$ 1,414.7	\$ 2,092.6	\$ (243.1)	\$ 1,849.5	\$ (416.9)	\$ 53.4	\$ 1,486.0
Completed technology	594.2	(195.8)	398.4	664.9	(70.7)	594.2	(183.9)	21.8	432.1
Product trade names	184.5	(49.8)	134.7	183.7		183.7	(41.0)		142.7
Customer relationships	2,665.8	(821.1)	1,844.7	2,944.6	(300.4)	2,644.2	(778.5)	94.5	1,960.2
Non-compete contracts	4.6	(2.8)	1.8	4.6		4.6	(2.1)		2.5
Sub-total	5,299.1	(1,504.8)	3,794.3	5,890.4	(614.2)	5,276.2	(1,422.4)	169.7	4,023.5
Corporate trade names	323.5		323.5	397.6	(74.1)	323.5			323.5
Currency translation	189.9	(32.7)	157.2	232.4		232.4	(45.0)		187.4
Total	\$ 5,812.5	\$ (1,537.5)	\$ 4,275.0	\$ 6,520.4	\$ (688.3)	\$ 5,832.1	\$ (1,467.4)	\$ 169.7	\$ 4,534.4

The weighted average useful life of the intangibles at February 29, 2012 is as follows:

**Weighted
Average**

Edgar Filing: BIOMET INC - Form 10-Q

	<u>Useful Life</u>
Core technology	17 Years
Completed technology	11 Years
Product trade names	15 Years
Customer relationships	16 Years
Non-compete contracts	3 Years
Corporate trade names	Indefinite life

Expected amortization expense for the intangible assets stated above, for the years ending May 31, 2012 through 2016 is \$336.5 million, \$329.9 million, \$320.0 million, \$30.1 million, and \$291.6 million, respectively.

Note 6 Debt.

The terms and carrying value of each debt instrument at February 29, 2012 and May 31, 2011 are set forth below:

<i>(U.S. dollars and euros in millions)</i>	Maturity Date	Interest Rate	Currency	February 29, 2012	May 31, 2011
Debt Instruments					
European facilities	No Maturity Date	Interest Free	EUR	3.1	3.9
				\$ 4.1	\$ 5.6
Term loan facility	March 25, 2015	LIBOR + 3.00%	USD	\$ 2,240.6	\$ 2,258.1
Term loan facility	March 25, 2015	LIBOR + 3.00%	EUR	837.8	844.4
				\$ 1,125.4	\$ 1,206.3
Cash flow revolving credit facility	September 25, 2013	LIBOR + 2.25%	USD		
Cash flow revolving credit facility	September 25, 2013	LIBOR + 2.25%	USD/EUR	\$/	\$/
Asset-based revolving credit facility	September 25, 2013	LIBOR + 1.25%	USD		
Senior cash pay notes	October 15, 2017	10%	USD	\$ 761.0	\$ 761.0
Senior PIK toggle notes	October 15, 2017	10 ³ /8% / 11 ¹ /8%	USD	\$ 771.0	\$ 771.0
Senior subordinated notes	October 15, 2017	11 ⁵ /8%	USD	\$ 1,015.0	\$ 1,015.0
Premium on notes				\$ 3.0	\$ 3.3
Total debt				\$ 5,920.1	\$ 6,020.3

The Company currently elects to use 3-month LIBOR for setting the interest rates on the majority of its U.S. dollar and euro term loans. The 3-month LIBOR rate for the U.S. dollar term loan as of February 29, 2012 was 0.57%. The euro term loan had a 3-month LIBOR rate of 1.33% as of February 29, 2012. The Company's term loan facilities require payments each year in an amount equal to 1% of the original principal in equal calendar quarterly installments until maturity of the loan on March 25, 2015. Through February 29, 2012, the total amount of required payments under the Company's term loan facilities was \$26.6 million. The cash flow and asset-based revolving credit facilities and the notes do not have terms for mandatory principal pay downs. To calculate the U.S. dollar equivalent on outstanding balances, the Company used a currency conversion rate of 1 euro to \$1.3432 and \$1.4284, which represents the currency exchange rate from euros to U.S. dollars on February 29, 2012 and May 31, 2011, respectively.

The Company has the option to choose the frequency with which it resets and pays interest on its term loans. The Company currently pays interest on the majority of its term loans and interest rate swaps each calendar quarter. The remaining term loan interest is paid monthly. Interest on the notes is paid semiannually in October and April.

The Company's revolving borrowing base available under all debt facilities at February 29, 2012 was \$713.9 million, which is net of the remaining \$22.3 million commitment of the subsidiaries of Lehman Brothers Holding Inc. and borrowing base limitations relating to the asset-based revolving credit facility. During November 2011, ABN AMRO Bank terminated the European revolver facility due to the limited use of the facility.

As of February 29, 2012, \$37.2 million of financing fees related to the Company's credit agreement remained in long-term assets and continue to be amortized through interest expense over the remaining life of the credit agreement.

Each of Biomet, Inc.'s existing wholly owned domestic subsidiaries fully, unconditionally, jointly, and severally guarantee the senior cash pay and PIK toggle notes on a senior unsecured basis and the senior subordinated notes on a senior subordinated unsecured basis, in each case to the extent such subsidiaries guarantee Biomet, Inc.'s senior secured cash flow facilities. LVB Acquisition, Inc. is neither an issuer nor guarantor of the notes described within this footnote.

Note 7 Fair Value Measurements.***Assets and Liabilities Measured at Fair Value on a Recurring Basis***

Fair value measurements are principally applied to (1) financial assets and liabilities such as marketable equity securities and debt securities, (2) investments in equity and other securities, and (3) derivative instruments consisting of interest rate swaps. These items are marked-to-market at each reporting period at fair value. The information in the following paragraphs and tables primarily addresses matters relative to these financial assets and liabilities.

Edgar Filing: BIOMET INC - Form 10-Q

Level 1 Inputs are quoted prices in active markets for identical assets or liabilities. The Company's Level 1 assets include money market investments and marketable equity securities.

Level 2 Inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. The Company's Level 2 assets and liabilities primarily include agency

Note 7 Fair Value Measurements, Continued.

bonds, corporate debt securities, asset-backed securities, certain mortgage-backed securities, time deposit, Greek bonds, interest rate swaps, pension plan assets (equity securities, debt securities and other) and foreign currency exchange contracts whose value is determined using a pricing model with inputs that are observable in the market or can be derived principally from or corroborated by observable market data.

Level 3 Inputs are unobservable for the asset or liability. The Company's Level 3 assets include other equity investments. See the section below titled *Level 3 Valuation Techniques* for further discussion of how the Company determines fair value for investments classified as Level 3.

The following table provides information by level for assets and liabilities that are measured at fair value on a recurring basis at February 29, 2012 and May 31, 2011:

(in millions)	Fair Value at February 29, 2012	Fair Value Measurements Using Inputs Considered as		
		Level 1	Level 2	Level 3
Assets:				
Money market funds	\$ 184.6	\$ 184.6	\$	\$
Greek bonds	7.8		7.8	
Pension plan assets	106.2		106.2	
Foreign currency exchange contracts	0.2		0.2	
Other	0.4	0.2		0.2
Total assets	\$ 299.2	\$ 184.8	\$ 114.2	\$ 0.2
Liabilities:				
Interest rate swaps	\$ 69.2	\$	\$ 69.2	\$
Foreign currency exchange contracts	0.1		0.1	
Total liabilities	\$ 69.3	\$	\$ 69.3	\$

(in millions)	Fair Value at May 31, 2011	Fair Value Measurements Using Inputs Considered as		
		Level 1	Level 2	Level 3
Assets:				
Corporate debt securities	\$ 0.3	\$	\$ 0.3	\$
Money market funds	132.5	132.5		
Time deposit	47.4		47.4	
Greek bonds	31.1		31.1	
Pension plan assets	104.1		104.1	
Foreign currency exchange contracts	0.2		0.2	
Other	0.5	0.3		0.2
Total assets	\$ 316.1	\$ 132.8	\$ 183.1	\$ 0.2
Liabilities:				
Interest rate swaps	\$ 96.8	\$	\$ 96.8	\$
Foreign currency exchange contracts	0.1		0.1	
Total liabilities	\$ 96.9	\$	\$ 96.9	\$

Level 3 Valuation Techniques

Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. Level 3 financial assets also include certain investment securities for which there is limited market activity where the determination of fair value requires significant judgment or estimation. Level 3 investment securities primarily include other equity investments for which there was a decrease in the observation of market pricing. As of February 29, 2012 and May 31, 2011, these securities were valued primarily using internal cash flow valuation that incorporates transaction details such as contractual terms, maturity, timing and amount of future cash flows, as well as assumptions about liquidity and credit valuation adjustments of marketplace participants.

Note 7 Fair Value Measurements, Continued.

The following table provides a reconciliation of the beginning and ending balances of items measured at fair value on a recurring basis in the tables above that used significant unobservable inputs (Level 3):

(in millions)

Balance at May 31, 2010	\$ 5.7
Total net gains included in earnings	2.6
Total unrealized gains included in other comprehensive income	(2.6)
Total proceeds from sale of Level 3 investments	(5.5)
Balance at February 28, 2011	\$ 0.2

(in millions)

Balance at May 31, 2011	\$ 0.2
Total net gains included in earnings	
Total unrealized gains included in other comprehensive income	
Total proceeds from sale of Level 3 investments	
Balance at February 29, 2012	\$ 0.2

The estimated fair value of the Company's long-term debt, including the current portion, at February 29, 2012 was \$6,149.8 million, compared to a carrying value of \$5,920.1 million, and was \$6,314.9 million, compared to a carrying value of \$6,020.3 million at May 31, 2011. The fair value of the Company's traded debt was estimated using quoted market prices for the same or similar instruments. The fair value of the Company's variable rate term debt was estimated using the carrying value as this debt has rates which approximate market interest rates. In determining the fair values and carrying values, the Company considers the terms of the related debt and excludes the impacts of debt discounts and interest rate swaps.

Assets and Liabilities that are Measured at Fair Value on a Nonrecurring Basis

During the three and nine months ended February 29, 2012 and February 28, 2011, the Company had no significant measurements of assets or liabilities at fair value on a nonrecurring basis subsequent to their initial recognition.

Note 8 Derivative Instruments and Hedging Activities.

The Company is exposed to certain market risks relating to its ongoing business operations, including foreign currency risk, interest rate risk and commodity price risk. The Company currently manages foreign currency risk and interest rate risk through the use of derivatives.

Derivatives Designated as Hedging Instruments

Foreign Currency Instruments Certain assets, liabilities and forecasted transactions are exposed to foreign currency risk, primarily the fluctuation of the U.S. dollar against the euro. The Company has hedged a portion of its net investment in its European subsidiaries with the issuance of a \$75.0 million (approximately \$1,207.4 million at September 25, 2007) principal amount euro term loan on September 25, 2007. The Company's net investment in its European subsidiaries at the hedging date of September 25, 2007 was \$1,238.0 million (\$1,690.0 million). As of February 29, 2012, the Company's net investment in European subsidiaries totaled \$1,778.9 million (\$2,389.4 million) and the outstanding principal balance of the euro term loan was \$837.8 million (\$1,125.4 million). The difference of \$941.1 million (\$1,264.0 million) is unhedged as of February 29, 2012. Hedge effectiveness is tested quarterly to determine whether hedge treatment is still appropriate. The Company tests effectiveness on this net investment hedge by determining if the net investment in its European subsidiaries is greater than the outstanding euro-denominated debt balance. Any amount of a derivative instrument designated as a hedge determined to be ineffective is recorded as other (income) expense.

Edgar Filing: BIOMET INC - Form 10-Q

Interest Rate Instruments The Company uses interest rate swap agreements (cash flow hedges) in both U.S. dollars and euros as a means of fixing the interest rate on portions of its floating-rate debt instruments. As of February 29, 2012, the Company had a swap liability of \$69.2 million, which consisted of \$45.5 million short-term, and \$24.4 million long-term, partially offset by a \$0.7 million credit valuation adjustment. As of May 31, 2011, the Company had a swap liability of \$96.8 million, which consisted of \$62.6 million short-term, and \$34.8 million long-term, partially offset by a \$0.6 million credit valuation adjustment.

Note 8 Derivative Instruments and Hedging Activities, Continued.

The table below summarizes existing swap agreements:

(U.S. dollars and euros in millions)

Structure	Currency	Notional Amount	Effective Date	Termination Date	Fair Value at February 29, 2012	Fair Value at May 31, 2011
					Asset (Liability)	Asset (Liability)
4 year	EUR	75.0	September 25, 2007	September 25, 2011	\$	\$ (1.7)
4 year	EUR	40.0	March 25, 2008	March 25, 2012	(0.4)	(1.4)
5 year	EUR	230.0	September 25, 2007	September 25, 2012	(8.1)	(13.6)
5 year	EUR	40.0	March 25, 2008	March 25, 2013	(2.1)	(2.5)
5 year	EUR	200.0	September 25, 2012	September 25, 2017	(3.0)	
5 year	EUR	200.0	September 25, 2012	September 25, 2017	(2.8)	
4 year	USD	\$ 140.0	September 25, 2007	September 25, 2011		(3.1)
4 year	USD	140.0	March 25, 2008	March 25, 2012	(0.2)	(3.0)
5 year	USD	585.0	September 25, 2007	September 25, 2012	(16.0)	(37.3)
5 year	USD	190.0	March 25, 2008	March 25, 2013	(5.6)	(9.3)
5 year	USD	325.0	December 26, 2008	December 25, 2013	(11.6)	(13.3)
5 year	USD	195.0	September 25, 2009	September 25, 2014	(12.5)	(12.2)
2 year	USD	190.0	March 25, 2013	March 25, 2015	(0.5)	
3 year	USD	270.0	December 27, 2013	September 25, 2016	(1.2)	
5 year	USD	350.0	September 25, 2012	September 25, 2017	(3.0)	
5 year	USD	350.0	September 25, 2012	September 25, 2017	(2.9)	
Credit valuation adjustment					0.7	0.6
Total interest rate instruments					\$ (69.2)	\$ (96.8)

The interest rate swaps are recorded in other accrued expenses and other long-term liabilities. As a result of cash flow hedge treatment being applied, all unrealized gains and losses related to the derivative instruments are recorded in accumulated other comprehensive income (loss) and are reclassified into operations in the same period in which the hedged transaction affects earnings. Hedge effectiveness is tested quarterly to determine if hedge treatment is still appropriate. The amount of ineffectiveness was not material for any period presented. The tables below summarize the effective portion and ineffective portion of the Company's interest rate swaps for the three and nine months ended February 29, 2012:

(in millions)

Derivatives in cash flow hedging relationship	Three Months Ended February 29, 2012	Nine Months Ended February 29, 2012
Interest rate swaps, net of tax:		
Amount of gain (loss) recognized in OCI	\$ (0.6)	\$ 17.4
Amount of (gain) loss reclassified from accumulated OCI into interest expense (effective portion)		
Amount (gain) loss recognized in other income (expense) (ineffective portion and amount excluded from effectiveness testing)		

As of February 29, 2012, the effective interest rate, including the applicable lending margin, on 64.05% (\$1,435.0 million) of the outstanding principal of the Company's U.S. dollar term loan was fixed at 6.76% through the use of interest rate swaps. The effective interest rate on 37.00% (\$310.0 million) of the outstanding principal of the Company's euro term loan was fixed at 7.31% through the use of interest rate swaps. The remaining unhedged balances of the U.S. dollar and euro term loans had effective interest rates of 3.24% and 3.52%, respectively. As of February 29, 2012 and May 31, 2011, the Company's effective weighted average interest rate on all outstanding debt, including the interest rate swaps, was 7.87% and 7.96%, respectively.

Derivatives Not Designated as Hedging Instruments

Edgar Filing: BIOMET INC - Form 10-Q

Foreign Currency Instruments The Company faces transactional currency exposures that arise when it or its foreign subsidiaries enter into transactions, primarily on an intercompany basis, denominated in currencies other than their functional currency. The Company enters into short-term forward currency exchange contracts in order to mitigate the currency exposure related to these intercompany payables and receivables arising from intercompany trade. The Company does not designate these contracts as hedges; therefore, all forward currency exchange contracts are recorded at their fair value each period, with the resulting gains and losses recorded in other (income) expense. Any foreign currency remeasurement gains or losses recognized in a period are generally offset with gains or losses on the forward currency exchange contracts. As of February 29, 2012, the fair value of the Company's derivatives not designated as hedging instruments on a gross basis were assets of \$0.2 million recorded in prepaid expenses and other and liabilities of \$0.1 million recorded in other accrued expenses.

Note 9 Accumulated Other Comprehensive Income (Loss).

Other comprehensive income (loss) includes net loss, currency translation adjustments, certain derivative-related activity, changes in the value of available-for-sale investments, and changes in prior service cost from pension plans. The Company generally deems its foreign investments to be essentially permanent in nature and does not provide for taxes on currency translation adjustments arising from translating the investment in a foreign currency to U.S. dollars. When the Company determines that a foreign investment is no longer permanent in nature, estimated taxes are provided for the related deferred tax liability (asset), if any, resulting from currency translation adjustments.

Accumulated other comprehensive income (loss) and the related components are included in the table below:

<i>(in millions)</i>	Balance at May 31, 2011	Other Comprehensive Income (Loss)	Balance at February 29, 2012
Unrecognized actuarial gain (loss) on pension assets, net of tax	\$ 1.2	\$ (0.3)	\$ 0.9
Foreign currency translation adjustments	235.8	(26.8)	209.0
Unrealized gain (loss) on interest rate swaps, net of tax	(60.4)	17.4	(43.0)
Unrealized loss on available-for-sale securities, net of tax	(4.8)	4.4	(0.4)
Accumulated other comprehensive income (loss)	\$ 171.8	\$ (5.3)	\$ 166.5

Note 10 Stock-based Compensation and Stock Plans.

The Company expenses all stock-based payments to employees and non-employee distributors, including stock options, leveraged share awards and restricted stock units, based on the grant date fair value over the required award service period using the graded vesting attribution method. For awards with a performance vesting condition, the Company recognizes expense when the performance condition is considered probable to occur. Stock-based compensation expense recognized was \$3.5 million and \$5.2 million for the three months ended February 29, 2012 and February 28, 2011, respectively, and \$12.2 million and \$14.6 million for the nine months ended February 29, 2012 and February 28, 2011, respectively.

Note 11 Income Taxes.

The Company applies guidance issued by the FASB for uncertainty in income taxes. The Company records the liability for unrecognized tax benefits (UTBs) as a long-term liability.

The Company conducts business globally and, as a result, certain of its subsidiaries file income tax returns in the U.S. federal jurisdiction, and various state and foreign jurisdictions. In the normal course of business, the Company is subject to examinations by tax and regulatory authorities throughout the world, including major jurisdictions such as Australia, Canada, France, Germany, Japan, the Netherlands, Spain, the United Kingdom and the United States.

The Internal Revenue Service has completed its examination relating to the Company's U.S. federal income tax returns for the tax years ended May 31, 2007, July 11, 2007 and May 31, 2008. The Company is no longer subject to U.S. federal income tax examinations for the tax years prior to and including the year ended May 31, 2002, as well as May 31, 2005 and May 31, 2006.

The Company regularly reviews issues that are raised from ongoing examinations and open tax years to evaluate the adequacy of its liabilities. As the various tax authorities continue with their audit/examination programs, the Company will adjust its reserves accordingly to reflect these settlements. As of February 29, 2012, the Company believes that it is reasonably possible that its worldwide gross liabilities for UTBs may decrease by up to \$23.0 million within the succeeding twelve months due to potential tax settlements. Substantially all of the Company's UTBs as of February 29, 2012, if recognized, would affect its effective tax rate.

The Company's effective income tax rate was (161.9)% and 20.9% for the three and nine months ended February 29, 2012 compared to 55.6% and 60.9% for the three and nine months ended February 28, 2011. The primary factor in determining the effective tax rate is the mix of various jurisdictions in which profits are projected to be earned and taxed. The Company's effective income tax rates for the three and nine months ended February 29, 2012 are lower than the effective income tax rates for the three and nine months ended February 28, 2011 primarily due to the tax impact of projected income inclusions related to U.S. anti-deferral provisions as well as updated assertions regarding the expected repatriation of earnings of the Company's foreign operations. Fluctuations in effective tax rates between comparable periods also reflect the discrete tax benefit

Edgar Filing: BIOMET INC - Form 10-Q

or expense of items in continuing operations that represent tax effects not attributable to current year ordinary income. The impact of discrete items on the Company's effective income tax rate was 84.4% and 18.7% for the three and nine months ended February 29, 2012 compared to (24.1)% and (0.2)% for the three and nine months ended February 28, 2011.

Note 12 Segment Reporting.

The Company operates in one reportable segment, musculoskeletal products, which includes the designing, manufacturing and marketing of large joint reconstructive; sports, extremities and trauma (S.E.T.); spine and bone healing; dental and other products. Other products consist primarily of microfixation products, autologous therapies, general instruments and operating room supplies. The Company operates in various geographies. These geographic markets are comprised of the United States, Europe and International. Major markets included in the International geographic market are Canada, South America, Mexico and the Asia Pacific region.

Net sales by product category for the three and nine months ended February 29, 2012 and February 28, 2011 were as follows:

<i>(in millions)</i>	Three Months Ended		Nine Months Ended	
	February 29, 2012 ⁽¹⁾	February 28, 2011 ⁽¹⁾	February 29, 2012 ⁽¹⁾	February 28, 2011 ⁽¹⁾
Net sales by product:				
Large Joint Reconstructive	\$ 422.7	\$ 402.6	\$ 1,259.2	\$ 1,205.1
S.E.T.	92.7	80.2	258.2	228.0
Spine & Bone Healing	76.5	80.6	230.1	247.2
Dental	65.6	67.2	198.5	195.5
Other	51.4	47.4	152.6	141.2
Total	\$ 708.9	\$ 678.0	\$ 2,098.6	\$ 2,017.0

⁽¹⁾ New product categories were adopted in order to more closely represent the way the Company reports sales and markets products. Certain amounts have been reclassified to conform to the current presentation.

Net sales by geography for the three and nine months ended February 29, 2012 and February 28, 2011 were as follows:

<i>(in millions)</i>	Three Months Ended		Nine Months Ended	
	February 29, 2012	February 28, 2011	February 29, 2012	February 28, 2011
Net sales by geography:				
United States	\$ 432.8	\$ 412.3	\$ 1,273.8	\$ 1,247.6
Europe	176.7	173.0	520.3	499.0
International ⁽¹⁾	99.4	92.7	304.5	270.4
Total	\$ 708.9	\$ 678.0	\$ 2,098.6	\$ 2,017.0

⁽¹⁾ International primarily includes Canada, South America, Mexico and the Asia Pacific region.

Long-term assets by geography as of February 29, 2012 and May 31, 2011 were as follows:

<i>(in millions)</i>	February 29, 2012	May 31, 2011
Long-term assets ⁽¹⁾ by geography:		

Edgar Filing: BIOMET INC - Form 10-Q

United States	\$ 7,005.7	\$ 7,199.7
Europe	1,125.7	1,233.7
International	1,187.9	1,209.5
Total	\$ 9,319.3	\$ 9,642.9

(1) Defined as property, plant and equipment, intangibles and goodwill.

Note 13 Guarantor and Non-Guarantor Financial Statements.

Each of Biomet, Inc.'s existing wholly owned domestic subsidiaries fully, unconditionally, jointly, and severally guarantee the senior cash pay and PIK toggle notes on a senior unsecured basis and the senior subordinated notes on a senior subordinated unsecured basis, in each case to the extent such subsidiaries guarantee Biomet, Inc.'s senior secured cash flow facilities. LVB Acquisition, Inc. is neither an issuer nor guarantor of the notes described in Note 6.

The following financial information illustrates the composition of the combined guarantor subsidiaries:

CONSOLIDATING BALANCE SHEETS

<i>(in millions)</i>	February 29, 2012				
	Biomet, Inc.	Guarantors	Non-Guarantors	Eliminations	Total
Assets					
Current assets:					
Cash and cash equivalents	\$	\$ 217.8	\$ 278.2	\$	\$ 496.0
Accounts receivable, net		241.7	265.7		507.4
Investments			3.8		3.8
Income tax receivable		1.7	1.4		3.1
Inventories, net		284.2	405.7	(134.1)	555.8
Deferred income taxes		62.9	9.4		72.3
Prepaid expenses and other		60.9	50.5		111.4
Total current assets		869.2	1,014.7	(134.1)	1,749.8
Property, plant and equipment, net		310.7	300.8	(12.6)	598.9
Investments		10.3	4.0		14.3
Investment in subsidiaries	9,152.9			(9,152.9)	
Intangible assets, net		3,246.8	1,028.2		4,275.0
Goodwill		3,460.8	984.6		4,445.4
Other assets		48.3	6.9		55.2
Total assets	\$ 9,152.9	\$ 7,946.1	\$ 3,339.2	\$ (9,299.6)	\$ 11,138.6
Liabilities & Shareholders Equity					
Current liabilities:					
Current portion of long-term debt	\$ 35.1	\$	\$ 1.5	\$	\$ 36.6
Accounts payable		46.4	38.8		85.2
Accrued interest	125.8				125.8
Accrued wages and commissions		53.8	44.3		98.1
Other accrued expenses		150.5	70.6		221.1
Total current liabilities	160.9	250.7	155.2		566.8
Long-term debt	5,880.9		2.6		5,883.5
Deferred income taxes		1,044.8	325.6		1,370.4
Other long-term liabilities		174.0	32.8		206.8
Total liabilities	6,041.8	1,469.5	516.2		8,027.5
Shareholders equity	3,111.1	6,476.6	2,823.0	(9,299.6)	3,111.1
Total liabilities and shareholders equity	\$ 9,152.9	\$ 7,946.1	\$ 3,339.2	\$ (9,299.6)	\$ 11,138.6

Note 13 Guarantor and Non-Guarantor Financial Statements, Continued.

<i>(in millions)</i>	May 31, 2011				
	Biomet, Inc.	Guarantors	Non-Guarantors	Eliminations	Total
Assets					
Current assets:					
Cash and cash equivalents	\$	\$ 176.4	\$ 151.4	\$	\$ 327.8
Accounts receivable, net		221.6	258.5		480.1
Investments		33.4	8.0		41.4
Income tax receivable		4.1	1.3		5.4
Inventories, net		292.1	414.7	(124.3)	582.5
Deferred income taxes		60.3	11.2		71.5
Prepaid expenses and other		57.1	52.6		109.7
Total current assets		845.0	897.7	(124.3)	1,618.4
Property, plant and equipment, net		332.5	315.8	(9.9)	638.4
Investments		10.0	23.1		33.1
Investment in subsidiaries	9,253.9			(9,253.9)	
Intangible assets, net		3,416.6	1,117.8		4,534.4
Goodwill		3,460.8	1,009.3		4,470.1
Other assets		56.3	6.3		62.6
Total assets	\$ 9,253.9	\$ 8,121.2	\$ 3,370.0	\$ (9,388.1)	\$ 11,357.0
Liabilities & Shareholder's Equity					
Current liabilities:					
Current portion of long-term debt	\$ 35.9	\$	\$ 1.5	\$	\$ 37.4
Accounts payable		48.1	43.0		91.1
Accrued interest	64.1				64.1
Accrued wages and commissions		56.7	48.3		105.0
Other accrued expenses		153.5	88.3		241.8
Total current liabilities	100.0	258.3	181.1		539.4
Long-term debt	5,978.8		4.1		5,982.9
Deferred income taxes		1,126.1	361.5		1,487.6
Other long-term liabilities		130.8	41.2		172.0
Total liabilities	6,078.8	1,515.2	587.9		8,181.9
Shareholder's equity	3,175.1	6,606.0	2,782.1	(9,388.1)	3,175.1
Total liabilities and shareholder's equity	\$ 9,253.9	\$ 8,121.2	\$ 3,370.0	\$ (9,388.1)	\$ 11,357.0

Edgar Filing: BIOMET INC - Form 10-Q

Operating income (loss)		83.3	(39.6)	240.9	284.6
Other (income) expense, net	360.6	1.5	10.6		372.7
Income (loss) before income taxes	(360.6)	81.8	(50.2)	240.9	(88.1)
Tax expense (benefit)	(115.0)	26.0	(7.5)	78.1	(18.4)
Equity in earnings of subsidiaries	175.9			(175.9)	
Net income (loss)	\$ (69.7)	\$ 55.8	\$ (42.7)	\$ (13.1)	\$ (69.7)

Note 13 Guarantor and Non-Guarantor Financial Statements, Continued.

	0000000	0000000	0000000	0000000	0000000
	Nine Months Ended February 28, 2011				
<i>(in millions)</i>	Biomet, Inc.	Guarantors	Non-Guarantors	Eliminations	Total
Net sales	\$	\$ 1,290.1	\$ 726.9	\$	\$ 2,017.0
Cost of sales		394.0	381.5	(165.9)	609.6
Gross profit		896.1	345.4	165.9	1,407.4
Operating expenses		748.9	388.1		1,137.0
Operating income (loss)		147.2	(42.7)	165.9	270.4
Other (income) expense, net	370.6	(5.6)			365.0
Income (loss) before income taxes	(370.6)	152.8	(42.7)	165.9	(94.6)
Tax expense (benefit)	(118.2)	48.7	(6.4)	18.3	(57.6)
Equity in earnings of subsidiaries	215.4			(215.4)	
Net income (loss)	\$ (37.0)	\$ 104.1	\$ (36.3)	\$ (67.8)	\$ (37.0)

CONSOLIDATING STATEMENTS OF CASH FLOWS

	0000000	0000000	0000000	0000000	0000000
	Nine Months Ended February 29, 2012				
<i>(in millions)</i>	Biomet, Inc.	Guarantor	Non-Guarantors	Eliminations	Total
Cash flows provided by (used in) operating activities	\$ 0.1	\$ 275.6	\$ 28.5	\$ (12.9)	\$ 291.3
Cash flows provided by (used in) investing activities	27.7	(234.2)	111.9	12.9	(81.7)
Cash flows used in financing activities	(27.8)		(1.1)		(28.9)
Effect of exchange rate changes on cash			(12.5)		(12.5)
Increase (decrease) in cash and cash equivalents		41.4	126.8		168.2
Cash and cash equivalents, beginning of period		176.4	151.4		327.8
Cash and cash equivalents, end of period	\$	\$ 217.8	\$ 278.2	\$	\$ 496.0

	0000000	0000000	0000000	0000000	0000000
	Nine Months Ended February 28, 2011				
<i>(in millions)</i>	Biomet, Inc.	Guarantor	Non-Guarantors	Eliminations	Total
Cash flows provided by (used in) operating activities	\$ 32.8	\$ 292.0	\$ 46.2	\$ (67.8)	\$ 303.2
Cash flows provided by (used in) investing activities	5.5	(209.6)	(39.5)	67.8	(175.8)
Cash flows used in financing activities	(38.3)		(1.3)		(39.6)
Effect of exchange rate changes on cash			10.8		10.8
Increase (decrease) in cash and cash equivalents		82.4	16.2		98.6
Cash and cash equivalents, beginning of period		103.5	85.6		189.1
Cash and cash equivalents, end of period	\$	\$ 185.9	\$ 101.8	\$	\$ 287.7

Note 14 Restructuring.

The Company recorded \$0.3 million and \$3.3 million in employee severance costs during the three months ended February 29, 2012 and February 28, 2011, respectively, and \$18.7 million and \$7.2 million during the nine months ended February 29, 2012 and February 28, 2011, respectively. The expense for the three and nine months ended February 29, 2012 resulted primarily from the global reconstructive products reorganization program and the planned closure of the Swindon, United Kingdom manufacturing facility. The reorganization program included the reorganization of the Company's domestic and international reconstructive products corporate structure described in Note 5. During November 2011, the Company commenced plans to close the manufacturing facility in Swindon, United Kingdom in a continued effort to maximize utilization of its plant network. The expense during the three and nine months ended February 28, 2011 related primarily to the transition of the Company's trauma hardware business from its Parsippany, New Jersey operations to its Warsaw, Indiana-based U.S. Reconstructive division. These restructuring charges were recorded within cost of sales; selling, general and administrative expense; and research and development expense. A summary of the severance and benefit costs in the periods presented is as follows:

<i>(in millions)</i>	Employee Severance and Benefit Costs
Restructuring Accrual:	
Balance at May 31, 2011	\$ 5.9
Costs incurred and charged to expense	8.2
Costs paid or otherwise settled	(2.2)
Non-cash adjustments ⁽¹⁾	0.2
Balance at August 31, 2011	12.1
Costs incurred and charged to expense	10.2
Costs paid or otherwise settled	(7.8)
Non-cash adjustments ⁽¹⁾	(1.5)
Balance at November 30, 2011	13.0
Costs incurred and charged to expense	0.3
Costs paid or otherwise settled	(3.0)
Non-cash adjustments ⁽¹⁾	
Balance at February 29, 2012	\$ 10.3

⁽¹⁾ Primarily related to foreign currency fluctuations.

<i>(in millions)</i>	Employee Severance and Benefit Costs
Restructuring Accrual:	
Balance at May 31, 2010	\$ 2.8
Costs incurred and charged to expense	1.9
Costs paid or otherwise settled	(1.0)
Non-cash adjustments ⁽¹⁾	0.1
Balance at August 31, 2010	3.8
Costs incurred and charged to expense	2.0
Costs paid or otherwise settled	(0.9)
Non-cash adjustments ⁽¹⁾	0.1

Edgar Filing: BIOMET INC - Form 10-Q

Balance at November 30, 2010		5.0
Costs incurred and charged to expense		3.3
Costs paid or otherwise settled		(3.2)
Non-cash adjustments ⁽¹⁾		0.1
Balance at February 28, 2011	\$	5.2

⁽¹⁾ Primarily related to foreign currency fluctuations.

Note 15 Contingencies.

The Company is involved in various proceedings, legal actions and claims arising in the normal course of business, including proceedings related to product liability, governmental investigations, intellectual property, commercial litigation and other matters. The outcomes of these matters will generally not be known for an extended period of time. In certain of the legal proceedings, the claimants seek damages, as well as other compensatory relief, which could result in the payment of significant claims and settlements. For legal matters for which management has sufficient information to reasonably estimate the Company's future obligations, a liability representing management's best estimate of the probable cost, or the minimum of the range of probable losses when a best estimate within the range is not known, for the resolution of these legal matters is recorded. The estimates are based on consultation with legal counsel, previous settlement experience and settlement strategies. The Company's accrual for contingencies at

Note 15 Contingencies, Continued.

February 29, 2012 and May 31, 2011 of \$46.7 million and \$30.6 million, respectively, primarily relate to product liability claims, the Massachusetts U.S. Department of Justice EBI products investigation and the Foreign Corrupt Practices Act investigation discussed below for which the Company is subject to self-insured limits and has estimated a probable settlement amount, and in the case of the FCPA investigation has settled as described below.

Based on the advice of the Company's counsel in these matters, it is unlikely that the resolution of any of these matters and any liabilities in excess of amounts provided will be material to the Company's financial position, results of operations or cash flows.

Other than the Massachusetts U.S. Department of Justice EBI products investigation, for which the estimated loss is included in the accrual referenced above and the U.S. Department of Justice and U.S. Securities and Exchange Commission Foreign Corrupt Practices Act investigation, for which the full amount of the settlement described below is included in the accrual referenced above, given the relatively early stages of the other governmental investigations described below and the preliminary nature of the trade secret litigation discussed below, and the complexities involved in these matters, the Company is unable to estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i) what claims, if any will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect on the litigation.

U.S. Department of Justice Consulting Agreement Investigation

On September 27, 2007, Biomet entered into a Deferred Prosecution Agreement with the U.S. Attorney's Office for the District of New Jersey. The agreement concluded the government's investigation into whether consulting agreements between the largest orthopedic manufacturers and orthopedic surgeons who use joint reconstruction and replacement products may have violated the federal Anti-Kickback Statute.

Through the agreement, the U.S. Attorney's Office agreed not to prosecute Biomet in connection with this matter, provided that Biomet satisfied its obligations under the agreement over the 18 months following the date of the Deferred Prosecution Agreement. The agreement called for the appointment of an independent monitor to review Biomet's compliance with the agreement, particularly in relation to its consulting agreements. On March 27, 2009, the Deferred Prosecution Agreement expired and the complaint was dismissed with prejudice.

As part of the resolution of this matter, Biomet also entered into a Corporate Integrity Agreement with the Office of the Inspector General of the U.S. Department of Health and Human Services. The agreement requires the Company for five years subsequent to September 27, 2007 to continue to adhere to its Code of Business Conduct and Ethics and certain other provisions, including reporting requirements.

U.S. Department of Justice EBI Products Investigations and Other Matters

In February 2010, Biomet received a subpoena from the Office of the Inspector General of the U.S. Department of Health and Human Services requesting various documents relating to agreements or arrangements between physicians and the Company's Interpore Cross subsidiary for the period from 1999 through the present and the marketing and sales activities associated with Interpore Cross spinal products. Biomet is cooperating with the request of the Office of the Inspector General. The Company can make no assurances as to the time or resources that will be needed to devote to this inquiry or its final outcome.

In April 2009, Biomet received an administrative subpoena from the U.S. Attorney's Office for the District of Massachusetts requesting various documents relating primarily to the Medicare reimbursement of and certain business practices related to the Company's EBI subsidiary's non-invasive bone growth stimulators. It is the Company's understanding that competitors in the non-invasive bone growth stimulation market received similar subpoenas. The Company received subsequent subpoenas in connection with the investigation in September 2009, June 2010 and February 2011 along with several informal requests for information. Biomet has produced responsive documents and is fully cooperating in the investigation.

In April 2009, the Company became aware of a qui tam complaint alleging violations of the federal and various state False Claims Acts filed in the United States District Court for the District of Massachusetts, where it is currently pending. Biomet, Parent, and several of the Company's competitors in the non-invasive bone growth stimulation market were named as defendants in this action. The allegations in the complaint are similar in nature to certain categories of requested documents in the above-referenced administrative subpoenas. The U.S. government has not intervened in the action. The Company is vigorously defending this matter and intends to continue to do so.

Note 15 Contingencies, Continued.***U.S. Department of Justice Civil Division Investigation***

In September 2010, Biomet, received a Civil Investigative Demand (CID) issued by the U.S. Department of Justice Civil Division pursuant to the False Claims Act. The CID requests that the Company provide documents and testimony related to allegations that Biomet, OtisMed Corp. and Stryker Corp. have violated the False Claims Act relating to the marketing of, and payment submissions for, OtisMed's OtisKneeSM (a registered trademark of OtisMed) knee replacement system. The Company has produced responsive documents and is fully cooperating in the investigation.

U.S. Securities and Exchange Commission (SEC) Informal Investigation

On September 25, 2007, Biomet received a letter from the SEC informing the Company that it is conducting an informal investigation regarding possible violations of the Foreign Corrupt Practices Act in the sale of medical devices in certain foreign countries by companies in the medical devices industry. The Foreign Corrupt Practices Act prohibits U.S. companies and their officers, directors, employees, or shareholders acting on their behalf and agents from offering, promising, authorizing or making payments to foreign officials for the purpose of obtaining or retaining business abroad or otherwise obtaining favorable treatment and this law requires companies to maintain records which fairly and accurately reflect transactions and to maintain internal accounting controls. In many countries, hospitals and clinics are government-owned and healthcare professionals employed by such hospitals and clinics, with whom the Company regularly interacts, may meet the definition of a foreign official for purposes of the Foreign Corrupt Practices Act. On November 9, 2007, the Company received a letter from the Department of Justice requesting any information provided to the SEC be provided to the Department of Justice on a voluntary basis.

On March 26, 2012, Biomet entered into a Deferred Prosecution Agreement (DPA) with the U.S. Department of Justice (DOJ) and a Consent to Final Judgment (Consent Agreement) with the SEC related to these investigations by the DOJ and the SEC. Pursuant to the DPA, the DOJ has agreed not to prosecute the Company in connection with this matter, provided that the Company satisfies its obligations under the agreement over the next three years. In addition, pursuant to the terms of the DPA, an independent external compliance monitor will be appointed to review the Company's compliance with the DPA, particularly in relation to the Company's international sales practices, for at least the first 18 months of the three year term of the DPA. The Company has also agreed to pay a monetary penalty of \$17.3 million to resolve the charges brought by the DOJ. The terms of the DPA and the associated monetary penalty reflect the Company's full cooperation throughout the investigation.

The Company has contemporaneously reached a Consent Agreement with the SEC to settle civil claims related to this matter. As part of the Consent Agreement, Biomet has agreed to the SEC's entry of a Final Judgment requiring Biomet to disgorge profits and pay prejudgment interest in the aggregate amount of \$5.6 million.

Other Matters

In January 2009, Heraeus Kulzer GmbH initiated legal proceedings in Germany against Biomet and its subsidiary, Biomet Europe BV, alleging that the Company and Biomet Europe BV misappropriated Heraeus Kulzer trade secrets when developing its new lines of European bone cements. The lawsuit seeks damages in excess of 30 million and injunctive relief to preclude the Company from producing its current line of European bone cements. The Company is vigorously defending this matter and intends to continue to do so.

There are various other claims, lawsuits, disputes with third parties, investigations and pending actions involving various allegations against the Company incident to the operation of its business, principally product liability and intellectual property cases. Each of these matters is subject to various uncertainties, and it is possible that some of these matters may be resolved unfavorably to the Company. The Company accrues for losses that are deemed to be probable and subject to reasonable estimate.

Note 16 Related Parties.***Transactions with the Sponsor Group***

On December 18, 2006, Biomet, Inc. entered into an Agreement and Plan of Merger with LVB Acquisition, LLC, a Delaware limited liability company, which was subsequently converted to a corporation, LVB Acquisition, Inc., and LVB Acquisition Merger Sub, Inc., an Indiana corporation and a wholly-owned subsidiary of Parent (Purchaser), which agreement was amended and restated as of June 7, 2007 and which we refer to as the Merger Agreement. Pursuant to the Merger Agreement, on June 13, 2007, Purchaser commenced a cash tender offer (the Offer) to purchase all of Biomet, Inc.'s outstanding common shares, without par value (the Shares) at a price of \$46.00 per Share (the Offer Price) without interest and less any required withholding taxes. The Offer was made pursuant to Purchaser's offer to purchase dated June 13, 2007 and the

Edgar Filing: BIOMET INC - Form 10-Q

related letter of transmittal, each of which was filed with the SEC on June 13, 2007. In connection with the Offer, Purchaser entered into a credit agreement dated as of July 11, 2007 for a \$6,165.0 million senior secured term loan facility (the Tender Facility), maturing on June 6, 2008, and pursuant to which it

Note 16 Related Parties, Continued.

borrowed approximately \$4,181.0 million to finance a portion of the Offer and pay related fees and expenses. The Offer expired at midnight, New York City time, on July 11, 2007, with approximately 82% of the outstanding Shares having been tendered to Purchaser. At Biomet, Inc.'s special meeting of shareholders held on September 5, 2007, more than 91% of Biomet, Inc.'s shareholders voted to approve the proposed merger, and Parent acquired Biomet, Inc. on September 25, 2007 through a reverse subsidiary merger with Biomet, Inc. being the surviving company (the Merger). Subsequent to the acquisition, Biomet, Inc. became a subsidiary of Parent, which is controlled by LVB Acquisition Holding, LLC, or Holding, an entity controlled by a consortium of private equity funds affiliated with The Blackstone Group, Goldman, Sachs & Co., Kohlberg Kravis Roberts & Co., and TPG Capital (each a Sponsor and collectively, the Sponsors), and certain investors who agreed to co-invest with the Sponsors (the Co-Investors). These transactions, including the Merger and the Company's payment of any fees and expenses related to these transactions, are referred to collectively as the Transactions.

Management Services Agreement

Upon completion of the Transactions, Biomet entered into a management services agreement with certain affiliates of the Sponsors, pursuant to which such affiliates of the Sponsors or their successors assigns, affiliates, officers, employees, and/or representatives and third parties (collectively, the Managers) provide management, advisory, and consulting services to the Company. Pursuant to such agreement, the Managers received a transaction fee equal to 1% of total enterprise value of the Transactions for the services rendered by such entities related to the Transactions upon entering into the agreement, and the Sponsors receive an annual monitoring fee equal to 1% of the Company's annual Adjusted EBITDA (as defined in the credit agreement) as compensation for the services rendered and reimbursement for out-of-pocket expenses incurred by the Managers in connection with the agreement and the Transactions. The Company is required to pay the Sponsors the monitoring fee on a quarterly basis in arrears. The total amount of Sponsor fees was \$2.7 million and \$2.8 million for the three months ended February 29, 2012 and February 28, 2011, respectively, and \$7.5 million and \$7.7 million for the nine months ended February 29, 2012 and February 28, 2011, respectively. The Company may also pay certain subsequent fees to the Managers for advice rendered in connection with financings or refinancings (equity or debt), acquisitions, dispositions, spin-offs, split-offs, dividends, recapitalizations, an initial underwritten public offering and change of control transactions involving the Company or any of its subsidiaries. The management services agreement includes customary exculpation and indemnification provisions in favor of the Managers and their affiliates.

Amended and Restated Limited Liability Company Operating Agreement of Holding

On September 27, 2007, certain investment funds associated with or designated by the Sponsors (the Sponsor Funds) entered into an amended and restated limited liability company operating agreement, or the LLC Agreement, in respect of Holding. The LLC Agreement contains agreements among the parties with respect to the election of the Company's directors and the directors of its parent companies, restrictions on the issuance or transfer of interests in the Company and other corporate governance provisions (including the right to approve various corporate actions).

Pursuant to the LLC Agreement, each of the Sponsors has the right to nominate, and has nominated, two directors to Biomet's and LVB's Board of Directors and also is entitled to appoint one non-voting observer to the Board of Directors for so long as such Sponsor remains a member of Holding. In addition to their right to appoint non-voting observers to the Board of Directors, certain of the Sponsor Funds have certain other management rights to the extent that any such Sponsor Fund is required to operate as a venture capital operating company as defined in the regulations issued by the U.S. Department of Labor at Section 2510.3-101 of Part 2510 of Chapter XXV, Title 29 of the Code of Federal Regulations, or any successor regulations. Each Sponsor's right to nominate directors is freely assignable to funds affiliated with such Sponsor, and is assignable to non-affiliates of such Sponsor only if the assigning Sponsor transfers its entire interest in Holding not previously transferred and only with the prior written consent of the Sponsors holding at least 70% of the membership interests in Holding, or requisite Sponsor consent. In addition to their rights under the LLC Agreement, the Sponsors may also appoint one or more persons unaffiliated with any of the Sponsors to the Board of Directors. Following Purchaser's purchase of the Shares tendered in the Offer, the Sponsors jointly appointed Dane A. Miller, Ph.D. and Jeffrey R. Binder to the Board of Directors in addition to the two directors appointed by each of the Sponsors.

Pursuant to the LLC Agreement, each director has one vote for purposes of any Board of Directors action, and all decisions of the Board of Directors require the approval of a majority of the directors designated by the Sponsors. In addition, the LLC Agreement provides that certain major decisions regarding the Company or its parent companies require the requisite Sponsor consent.

The LLC Agreement includes certain customary agreements with respect to restrictions on the issuance or transfer of interests in Biomet and LVB, including preemptive rights, tag-along rights and drag-along rights.

Edgar Filing: BIOMET INC - Form 10-Q

The Co-Investors have also been admitted as members of Holding, both directly and through Sponsor-controlled investment vehicles. Although the Co-Investors are therefore parties to the LLC Agreement, they have no rights with respect to the election of Biomet's or LVB's directors or the approval of its corporate actions.

Note 16 Related Parties, Continued.

The Sponsors have also caused Holding and Parent to enter into an agreement with the Company obligating the Company and Parent to take all actions necessary to give effect to the corporate governance, preemptive rights, transfer restriction and certain other provisions of the LLC Agreement, and prohibiting the Company and Parent from taking any actions that would be inconsistent with such provisions of the LLC Agreement.

Registration Rights Agreement

The Sponsor Funds and the Co-Investors also entered into a registration rights agreement with Holding, LVB and Biomet upon the closing of the Transactions. Pursuant to this agreement, the Sponsor Funds have the power to cause Holding, LVB and Biomet to register their, the Co-Investors' and certain other persons' equity interests under the Securities Act and to maintain a shelf registration statement effective with respect to such interests. The agreement also entitles the Sponsor Funds and the Co-Investors to participate in any future registration of equity interests under the Securities Act that Holding, LVB or Biomet may undertake.

Management Stockholders' Agreements

On September 13, 2007 and November 6, 2007, Holding, LVB and the Sponsor Funds entered into stockholders agreements with certain of the Company's senior executives and other management stockholders. Pursuant to the terms of the LVB Acquisition, Inc. Management Equity Incentive Plan, participants who exercise their vested options are required to become parties to the agreement dated November 6, 2007. The stockholder agreements contain agreements among the parties with respect to restrictions on the transfer and issuance of shares, including preemptive, drag-along, tag-along, and call/put rights.

Consulting Agreements

On January 14, 2010, Biomet entered into a consulting agreement with Dr. Dane A. Miller Ph.D., pursuant to which it will pay Dr. Miller a consulting fee of \$0.25 million per fiscal year for Dr. Miller's consulting services and will reimburse Dr. Miller for out-of-pocket fees and expenses relating to an off-site office and administrative support in an amount of \$0.1 million per year. The term of the agreement extends through the earlier of September 1, 2011, an initial public offering or a change of control. The agreement also contains certain restrictive covenants prohibiting Dr. Miller from competing with the Company and soliciting employees of the Company during the term of the agreement and for a period of one year following such term. On September 6, 2011, the Company entered into an amendment to the consulting agreement with Dr. Miller, pursuant to which it agreed to increase the expenses relating to an off-site office and administrative support from \$0.1 million per year to \$0.15 million per year and extend the term of the agreement through the earlier of September 1, 2013, an initial public offering or a change of control. Dr. Miller received payments under the consulting agreement of \$0.1 million and \$0.3 million for the three and nine months ended February 29, 2012, respectively, and \$0.1 million and \$0.2 million for the three and nine months ended February 28, 2011, respectively.

Indemnification Priority Agreement

On January 11, 2010, Biomet and LVB entered into an indemnification priority agreement with the Sponsors (or certain affiliates designated by the Sponsors) pursuant to which Biomet and LVB clarified certain matters regarding the existing indemnification and advancement of expenses rights provided by Biomet and LVB pursuant to their respective charters and the management services agreement described above. In particular, pursuant to the terms of the indemnification agreement, Biomet acknowledged that as among Biomet, LVB and the Sponsors and their respective affiliates, the obligation to indemnify or advance expenses to any director appointed by any of the Sponsors will be payable in the following priority: Biomet will be the primary source of indemnification and advancement; LVB will be the secondary source of indemnification and advancement; and any obligation of a Sponsor-affiliated indemnitor to indemnify or advance expenses to such director will be tertiary to Biomet's and, then, LVB obligations. In the event that either Biomet or LVB fails to indemnify or advance expenses to any such director in contravention of its obligations, and any Sponsor-affiliated indemnitor makes any indemnification payment or advancement of expenses to such director on account of such unpaid liability, such Sponsor-affiliated indemnitor will be subrogated to the rights of such director under any such Biomet or LVB indemnification agreement.

Equity Healthcare

Effective January 1, 2009, Biomet entered into an employer health program agreement with Equity Healthcare LLC (Equity Healthcare). Equity Healthcare negotiates with providers of standard administrative services for health benefit plans as well as other related services for cost discounts and quality of service monitoring capability by Equity Healthcare. Because of the combined purchasing power of its client participants, Equity Healthcare is able to negotiate pricing terms for providers that are believed to be more favorable than the companies could

obtain for themselves on an individual basis.

Note 16 Related Parties, Continued.

In consideration for Equity Healthcare's provision of access to these favorable arrangements and its monitoring of the contracted third parties delivery of contracted services to the Company, the Company pays Equity Healthcare a fee of \$2 per participating employee per month (PEPM Fee). As of February 29, 2012, the Company had approximately 3,200 employees enrolled in its health benefit plans in the United States.

Equity Healthcare may also receive a fee (Health Plan Fees) from one or more of the health plans with whom Equity Healthcare has contractual arrangements if the total number of employees joining such health plans from participating companies exceeds specified thresholds. If and when Equity Healthcare reaches the point at which the aggregate of its receipts from the PEPM Fee and the Health Plan Fees have covered all of its allocated costs, it will apply the incremental revenues derived from all such fees to (a) reduce the PEPM Fee otherwise payable by the Company; (b) avoid or reduce an increase in the PEPM Fee that might otherwise have occurred on contract renewal; or (c) arrange for additional services to the Company at no cost or reduced cost.

Equity Healthcare is an affiliate of Blackstone, with whom Michael Dal Bello and David McVeigh, members of the Company's Board of Directors, are affiliated and in which they may have an indirect pecuniary interest.

There were payments of \$0.1 million made during the nine months ended February 29, 2012 with no payments made during the three months ended February 29, 2012 and payments of \$0.1 million made during the nine months ended February 28, 2011 with no payments made during the three months ended February 28, 2011.

Core Trust Purchasing Group Participation Agreement

Effective May 1, 2007, Biomet entered into a 5-year participation agreement (Participation Agreement) with Core Trust Purchasing Group, a division of HealthTrust Purchasing Corporation (CPG), designating CPG as the Company's exclusive group purchasing organization for the purchase of certain products and services from third party vendors. CPG secures from vendors pricing terms for goods and services that are believed to be more favorable than participants in the group purchasing organization could obtain for themselves on an individual basis. Under the participation agreement, the Company must purchase 80% of the requirements of its participating locations for core categories of specified products and services, from vendors participating in the group purchasing arrangement with CPG or CPG may terminate the contract. In connection with purchases by its participants (including the Company), CPG receives a commission from the vendors in respect of such purchases. The total amount of fees paid to CPG was \$0.1 million and \$0.3 million for the three and nine months ended February 29, 2012, respectively. The total amount of fees paid to CPG was \$0.1 million for both the three and nine months ended February 28, 2011.

Although CPG is not affiliated with Blackstone, in consideration for Blackstone's facilitating Biomet's participation in CPG and monitoring the services CPG provides to the Company, CPG remits a portion of the commissions received from vendors in respect of the Company's purchases under the Participation Agreement to an affiliate of Blackstone, with whom Michael Dal Bello and David McVeigh, members of the Company's Board of Directors, are affiliated and in which they may have an indirect pecuniary interest.

Other

Biomet currently holds interest rate swaps with Goldman Sachs. As part of this relationship, the Company receives information from Goldman Sachs that allows it to perform a regression on the swaps as part of its required effectiveness testing on a quarterly basis.

Biomet, Inc. may from time to time, depending upon market conditions, seek to purchase debt securities issued by Biomet or its subsidiaries in open market or privately negotiated transactions or by other means. Biomet understands that its indirect controlling stockholders may from time to time also seek to purchase debt securities issued by the Company or its subsidiaries in open market or privately negotiated transactions or by other means.

Periodically, Biomet charters a plane indirectly owned by Dane A. Miller, Ph.D., through a non-related third party charter service, for Biomet business related use. There were no payments made during the three and nine months ended February 29, 2012 and February 28, 2011.

The Company engaged Capstone Consulting LLC, a consulting company that works exclusively with KKR's portfolio companies to provide analysis for certain restructuring initiatives. The Company or its affiliates paid Capstone \$0.6 million and \$1.7 million during the three and nine months ended February 29, 2012, respectively, and no payments during the three and nine months ended February 28, 2011.

Note 16 Related Parties, Continued.

Capital Contributions and Share Repurchases

At the direction of LVB, Biomet funded the repurchase of common shares of its parent company of \$0.1 million and \$0.2 million for the three months ended February 29, 2012 and February 28, 2011, respectively, and \$1.2 million and \$1.2 million for the nine months ended February 29, 2012 and February 28, 2011, respectively, from former employees pursuant to the LVB Acquisition, Inc. Management Stockholders Agreement. There were no additional contributions for the three and nine months ended February 29, 2012 and February 28, 2011.

Note 17 Subsequent Event

On April 3, 2012 the Company announced that it made a binding offer to acquire the worldwide trauma business of DePuy Orthopaedics, Inc. Under the terms of the offer, which is subject to exclusivity protection, Biomet will pay approximately \$280.0 million in cash. The binding offer was made in order to permit DePuy Orthopaedics to comply with its consultation obligations with various European works councils prior to entering into a negotiated, mutually binding purchase agreement.

The binding offer expires on June 1, 2012 but can be extended under certain circumstances. The transaction is subject to receipt of regulatory approvals, completion of required employee consultation procedures and other customary closing conditions.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

We design, manufacture and market a comprehensive range of both surgical and non-surgical products used primarily by orthopedic surgeons and other musculoskeletal medical specialists. Our corporate headquarters are located in Warsaw, Indiana and we have manufacturing and/or office facilities in more than 50 locations worldwide and distribute products in approximately 90 countries.

Executive Overview

Our net sales increased 5% for the three months ended February 29, 2012 to \$708.9 million, compared to \$678.0 million for the three months ended February 28, 2011. The effect of foreign currency fluctuations negatively impacted reported net sales for the three months ended February 29, 2012 by \$1.8 million, with Europe reported net sales negatively impacted by \$3.5 million, or 2%, and International reported net sales positively impacted by \$1.6 million, or 2%. New product categories were adopted in order to more closely represent the way we report sales and market our products. The following represents key sales growth statistics for the three months ended February 29, 2012 compared to the three months ended February 28, 2011:

Large Joint Reconstructive product sales increased 5% worldwide and 6% in the U.S.

Sports, Extremities and Trauma (S.E.T.) product sales increased 16% worldwide and 15% in the U.S.

Spine & Bone Healing product sales decreased 5% worldwide and 5% in the U.S.

Dental product sales decreased 2% worldwide and increased 12% in the U.S.

Other product sales increased 8% worldwide and were flat in the U.S.

Our operating income for the three months ended February 29, 2012 was \$108.1 million, compared to \$94.9 million for the three months ended February 28, 2011. We continued to see positive mix in the U.S. primarily from our new hip products, which partially offset negative pricing pressure in our global Large Joint Reconstructive business. The increase in operating income was primarily due to a decrease in amortization expense, which was primarily a result of the intangible assets impairment charge of \$518.6 million in the fourth quarter of fiscal 2011, causing a decrease in the intangible asset balance remaining to be amortized, partially offset by an increase in restructuring expense related to the global reconstructive products reorganization program. The program included the reorganization of our domestic and international reconstructive products corporate structure. Net cash provided by operating activities was \$291.3 million for the nine months ended February 29, 2012, as compared to net cash provided of \$303.2 million for the nine months ended February 28, 2011. The decrease in cash provided by operating activities was primarily due to an increase in cash paid for taxes due to net operating losses being fully utilized in the United States and an increase in accounts receivable due to increased sales with an increase in days sales outstanding.

Opportunities and Challenges

Our results of operations could be substantially affected not only by global economic conditions, but also by local operating and economic conditions, which can vary substantially by market. Unfavorable conditions can depress sales in a given market and may result in actions that adversely affect our margins, constrain our operating flexibility or result in charges which are unusual or non-recurring. Certain macroeconomic events, such as the current adverse conditions in the global economy, could have a more wide-ranging and prolonged impact on the general business environment, which could also adversely affect us.

In the United States, healthcare providers that purchase our products (*e.g.*, hospitals, physicians, dentists and other health care providers) generally rely on payments from third-party payors (principally federal Medicare, state Medicaid and private health insurance plans) to cover all or a portion of the cost of our musculoskeletal products. In March 2010, comprehensive health care reform legislation was enacted through the Patient Protection and Affordable Health Care Act (H.R. 3590) and the Health Care and Education Reconciliation Act (H.R. 4872). Among other initiatives, these bills impose a 2.3% excise tax on domestic sales of medical devices following December 31, 2012, which is estimated to contribute approximately \$27 billion to healthcare reform. Various healthcare reform proposals have also emerged at the state level. Except for the excise tax, which will impact results of operations following December 31, 2012, we cannot predict with certainty what healthcare initiatives, if any, will be implemented at the state level, or what the ultimate effect of federal health care reform or any future legislation or

Edgar Filing: BIOMET INC - Form 10-Q

regulation will have on us. However, an expansion in government's role in the U.S. healthcare industry may lower reimbursements for our products, reduce medical procedure volumes and adversely affect our business and results of operations, possibly materially.

Outside the United States, reimbursement systems vary significantly from country to country. If adequate levels of reimbursement from third-party payors outside the United States are not obtained, international sales of our products may decline. Many foreign markets, including Canada and some European and Asian countries, have decreased reimbursement rates. Our ability to continue to sell certain products profitably in these markets may diminish if the government-managed healthcare systems continue to reduce reimbursement rates, which can decrease pricing and procedural volume.

European Sovereign Debt Crisis

We continue to monitor economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and our business, especially in light of the global economic downturn and European sovereign debt crisis. We believe the credit and economic conditions within Greece, Ireland, Italy, Portugal, Spain and Turkey, among other European Union countries, have continued to deteriorate. These conditions have resulted in, and may continue to result in, an increase in the average length of time that it takes to collect on our accounts receivable outstanding in these countries.

As of February 29, 2012, our orthopedic net accounts receivable in these six countries totaled over \$70.0 million. To date, we have not experienced any significant cash losses in the current fiscal year with respect to the collection of our accounts receivable related to sales within these countries.

We received \$45.5 million face value zero coupon bonds from the Greek government as payment for the outstanding accounts receivable balance from 2007-2009 related to certain government sponsored institutions in a non-cash transaction. Upon receipt, the bonds had a fair value of \$33.8 million, with maturity dates of one to three years. The bonds are designated as available-for-sale securities. We recorded realized losses of \$2.8 million and \$19.3 million on the Greek bonds related to other-than-temporary impairment for the three and nine months ended February 29, 2012, respectively, which is included in other (income) expense with no other-than-temporary impairment recorded for the three and nine months ended February 28, 2011. The one year bonds matured in December 2011 and we received the full par value of approximately \$8.4 million. The outstanding two year bonds were reclassified to short-term in December 2011 and were classified as long-term in the consolidated balance sheet at May 31, 2011. The outstanding three year bonds were classified as long-term in the consolidated balance sheet at February 29, 2012 and May 31, 2011. On March 9, 2012 the Greek government finalized the private sector involvement in the Greek debt restructuring. All holders of Greek government bonds are required to exchange the existing bonds to new bonds. The new bonds will have maturities ranging from 1 to 30 years with the face value reduced by 53%. At February 29, 2012 the face value of the bonds was \$36.4 million.

Seasonality

Our business is somewhat seasonal in nature, as many of our products are used in elective procedures, which typically decline during the summer months, particularly in European countries, and the winter holiday season.

Products

Our product portfolio encompasses large joint reconstructive, S.E.T., spine & bone healing, dental and other products.

Large Joint Reconstructive Products Orthopedic reconstructive implants are used to replace joints that have deteriorated as a result of disease (principally osteoarthritis) or injury. Reconstructive joint surgery involves the modification of the area surrounding the affected joint and the implantation of one or more manufactured components, and may involve the use of bone cement. Our large orthopedic reconstructive joints are knees and hips. We also produce bone cements and cement delivery systems.

S.E.T. We manufacture and distribute a number of sports medicine products (used in minimally-invasive orthopedic surgical procedures). Extremity reconstructive implants are used to replace joints other than hips and knees that have deteriorated as a result of disease or injury. Our key reconstructive joint in this product category is the shoulder, but we produce other joints as well. Trauma devices are used for setting and stabilizing bone fractures to support and/or augment the body's natural healing process. Trauma products include internal fixation devices (such as nails, plates, screws, pins and wires designed to stabilize traumatic bone injuries) and external fixation devices (utilized to stabilize fractures when alternative methods of fixation are not suitable).

Spine & Bone Healing Products Our spine products include spinal fixation systems for cervical, thoracolumbar, deformity correction and spacer applications; electrical stimulation devices for spinal applications; and osteobiologics, including bone substitute materials, as well as allograft services for spinal applications. Bone healing products include electrical stimulation devices used for trauma indications, offering implantable and non-invasive options to stimulate bone growth, as well as orthopedic support products (also referred to as bracing products).

Dental Products Dental reconstructive devices and associated instrumentation are used for oral rehabilitation through the replacement of teeth and repair of hard and soft tissues. We also offer crown and bridge products.

Other Products We manufacture and distribute a number of other products, including microfixation products, autologous therapies, operating room supplies, casting materials, general surgical instruments, wound care products and other surgical products.

Results of Operations

For the Three Months Ended February 29, 2012 Compared to the Three Months Ended February 28, 2011

<i>(in millions, except percentages)</i>	Three Months Ended February 29, 2012	Percentage of Net Sales	Three Months Ended February 28, 2011	Percentage of Net Sales	Percentage Increase/ (Decrease)
Net sales	\$ 708.9	100%	\$ 678.0	100%	5%
Cost of sales	219.7	31	208.1	31	6
Gross profit	489.2	69	469.9	69	4
Selling, general and administrative expense	268.4	38	252.9	37	6
Research and development expense	30.1	4	28.8	4	5
Amortization	82.6	12	93.3	14	(11)
Operating income	108.1	15	94.9	14	14
Interest expense	117.2	17	124.0	18	(5)
Other (income) expense	(2.8)		(3.0)		(7)
Other expense, net	114.4	16	121.0	18	(5)
Loss before income taxes	(6.3)	(1)	(26.1)	(4)	(76)
Provision (benefit) from income taxes	10.2	1	(14.5)	(2)	(170)
Net loss	\$ (16.5)	(2)%	\$ (11.6)	(2)%	42%

Sales

Net sales were \$708.9 million for the three months ended February 29, 2012, and \$678.0 million for the three months ended February 28, 2011. The following tables provide net sales by geography and product category:

Geography Sales Summary

<i>(in millions, except percentages)</i>	Three Months Ended February 29, 2012	Percentage of Net Sales	Three Months Ended February 28, 2011	Percentage of Net Sales	Percentage Increase/ (Decrease)
United States	\$ 432.8	61%	\$ 412.3	61%	5%
Europe	176.7	25	173.0	26	2
International ⁽¹⁾	99.4	14	92.7	13	7
Total	\$ 708.9	100%	\$ 678.0	100%	5%

⁽¹⁾ International primarily includes Canada, South America, Mexico and the Asia Pacific region.

Product Category Summary

Edgar Filing: BIOMET INC - Form 10-Q

<i>(in millions, except percentages)</i>	Three Months Ended February 29, 2012 ⁽¹⁾	Percentage of Net Sales	Three Months Ended February 28, 2011 ⁽¹⁾	Percentage of Net Sales	Percentage Increase/ (Decrease)
Large Joint Reconstructive	\$ 422.7	60%	\$ 402.6	59%	5%
Sports, Extremities, Trauma (S.E.T.)	92.7	13	80.2	12	16
Spine & Bone Healing	76.5	11	80.6	12	(5)
Dental	65.6	9	67.2	10	(2)
Other	51.4	7	47.4	7	8
Total	\$ 708.9	100%	\$ 678.0	100%	5%

⁽¹⁾ New product categories were adopted in order to more closely represent the way we report sales and market products. Certain amounts have been reclassified to conform to the current presentation.

Large Joint Reconstructive

Net sales of large joint reconstructive products for the three months ended February 29, 2012 was \$422.7 million, or 60% of net sales, representing a 5% increase compared to net sales of \$402.6 million, or 59% of net sales, during the three months ended February 28, 2011.

Knee product sales increased 4% worldwide and 4% in the United States during the three months ended February 29, 2012, compared to the three months ended February 28, 2011. The worldwide growth was primarily due to knee sales growth in

Europe and in the U.S. Europe sales growth was primarily due to increased sales of the Vanguard® Knee as well as the OSS Orthopaedic Salvage System. The sales increase in the U.S. was driven by increased sales in Vanguard® knee and also Vanguard® 360 revision knee offset partially by continued decreases in partial knees. We believe partial knee sales have declined due to macroeconomic conditions impacting patients and competitive activities with partial knee product offerings in the market place the last several years. The rate of decline year-over-year has decelerated, as we continue to focus on our sales and marketing execution in our partial knee business. We believe new technologies such as the Oxford® Microplasty® instruments and the Signature Personalized Patient Care System for Oxford® knee, are contributing to what we believe are the early signs of stabilization.

Hip product sales increased 6% worldwide and 7% in the United States during the three months ended February 29, 2012, compared to the three months ended February 28, 2011. We believe the sales increase was primarily driven by the strong market acceptance of the new Arcos® Modular Femoral Revision System, the new Active Articulation El system and our Taperloc® Complete Hip Stem, which more than offset the erosion of metal-on-metal hip sales.

Sales of bone cement and other reconstructive products increased 6% worldwide and 8% in the United States during the three months ended February 29, 2012, compared to the three months ended February 28, 2011. Strong sales of StageOne hip and knee cement spacer molds particularly the new StageOne Select modular hip spacer molds contributed to sales growth in the bone cement and other reconstructive product category.

S.E.T.

Worldwide net sales of S.E.T. products for the three months ended February 29, 2012 were \$92.7 million, or 13% of net sales, representing a 16% increase compared to net sales of \$80.2 million, or 12% of net sales, during the three months ended February 28, 2011.

Sports medicine sales increased 22% worldwide, with an 18% sales increase in the United States, during the three months ended February 29, 2012, compared to the three months ended February 28, 2011. The primary contributor of sales growth in the third quarter was the Juggernaut Soft Anchor due to increased volumes from strong market acceptance and expanded innovation of product offering beyond labral repair into rotator cuff.

Extremity product sales increased 18% worldwide, with a 21% sales increase in the United States, during the three months ended February 29, 2012, compared to the three months ended February 28, 2011. The Comprehensive® Primary and Reverse Shoulder Systems continued to drive strong sales growth for the extremity product category.

Trauma product sales increased 1% worldwide, with a 6% sales decrease in the United States, during the three months ended February 29, 2012, compared to the three months ended February 28, 2011. External fixation sales declined due to a continued market shift from external fixation to internal fixation products and competitive pressures, more than offset by increased internal fixation sales. The increased internal fixation sales were primarily due to strong sales of the OptiLock® VL Distal Radius Plating System.

Spine & Bone Healing

Worldwide net sales of spine & bone healing products for the three months ended February 29, 2012 were \$76.5 million, or 11% of net sales, representing a 5% decrease compared to net sales of \$80.6 million, or 12% of net sales, for the three months ended February 28, 2011. We believe the spine market continued to be affected by mid-single-digit price erosion, a slowdown in volumes due to the general economy, a challenging reimbursement environment for some fusion procedures, and a trend toward physician-owned distributorships.

Spine product sales decreased 3% worldwide and in the United States during the three months ended February 29, 2012, compared to the three months ended February 28, 2011.

Sales of bone healing products decreased 10% worldwide and in the United States during the three months ended February 29, 2012, compared to the three months ended February 28, 2011.

Dental

Worldwide net sales of dental products for the three months ended February 29, 2012 were \$65.6 million, or 9% of net sales, representing a 2% decrease compared to net sales of \$67.2 million, or 10% of net sales, during the three months ended February 28, 2011. The decreased dental sales are primarily due to decreases in the European market due to the economic uncertainty in the regions where we currently have the largest market share. The sales growth of 12% in the U.S. is due to volume growth in addition to increased average sales prices.

Other

Worldwide net sales of other products for the three months ended February 29, 2012 were \$51.4 million, or 7% of net sales, representing an 8% increase compared to net sales of \$47.4 million, also 7% of net sales, during the three months ended February 28, 2011. Our microfixation product sales grew during the quarter both worldwide and in the United States, which was partially offset by a decrease in sales of autologous therapies.

Gross Profit

Gross profit for the three months ended February 29, 2012 increased to \$489.2 million, compared to gross profit for the three months ended February 28, 2011 of \$469.9 million, or 69% of net sales for both periods. Gross profit as a percentage of net sales was slightly down compared to the three months ended February 28, 2011 due to a decrease in average selling prices, unfavorable manufacturing variances as production volumes were lower and costs related to the closure of the Swindon, United Kingdom plant that commenced during the second quarter of fiscal 2012.

Selling, General and Administrative Expense

Selling, general and administrative expense during the three months ended February 29, 2012 was \$268.4 million, compared to \$252.9 million for the three months ended February 28, 2011, or 38% and 37% of net sales, respectively. The expense was slightly up due to the costs related to settlement of the FCPA investigation.

Research and Development Expense

Research and development expense during the three months ended February 29, 2012 was \$30.1 million, compared to \$28.8 million for the three months ended February 28, 2011, or 4% of net sales for both periods. The slight increase in research and development expenses for the three months ended February 29, 2012 primarily related to our ongoing commitment to increase investment in clinical research and regulatory affairs within our business. Our principal research and development efforts relate to primary and revision orthopedic reconstructive devices, spinal fixation products, dental reconstructive devices, sports medicine products, resorbable technology, biomaterial products and autologous therapies.

Amortization

Amortization expense for the three months ended February 29, 2012 was \$82.6 million or 12% of net sales, compared to \$93.3 million for the three months ended February 28, 2011, or 14% of net sales. This decrease is primarily due to the intangible asset impairment charge taken in the fourth quarter of fiscal 2011 related to our Europe business.

Interest Expense

Interest expense was \$117.2 million for the three months ended February 29, 2012, compared to interest expense of \$124.0 million for the three months ended February 28, 2011. The decrease in interest expense was primarily due to a lower average interest rate on our term loan facilities as our interest rate swaps continue to mature moving more of our term loan facilities from fixed to floating rate debt.

Other (Income) Expense

Other (income) expense was income of \$2.8 million for the three months ended February 29, 2012, compared to income of \$3.0 million for the three months ended February 28, 2011.

Provision (Benefit) from Income Taxes

The effective income tax rate was (161.9)% for the three months ended February 29, 2012 compared to 55.6% for the three months ended February 28, 2011. The primary factor in determining the effective tax rate is the mix of various jurisdictions in which profits are projected to be earned and taxed. Our effective income tax rate for the three months ended February 29, 2012 is lower than the effective income tax rate for the three months ended February 28, 2011 primarily due to the tax impact of projected income inclusions related to U.S. anti-deferral provisions as well as updated assertions regarding the expected repatriation of earnings of our foreign operations. Fluctuations in effective tax rates between comparable periods also reflect the discrete tax benefit or expense of items in continuing operations that represent tax effects not attributable to current-year ordinary income. The tax benefit for the three months ended February 29, 2012 was increased due to discrete items, consisting primarily of restructuring-related adjustments and finalization of the 2010 income tax returns, and decreased as a result of an increase in the state tax rate applied to calculate deferred tax liabilities. The tax benefit for the three months ended February 28, 2011 was decreased due to the

settlement of an IRS audit and finalization of the 2009 income tax returns.

Edgar Filing: BIOMET INC - Form 10-Q

For the Nine Months Ended February 29, 2012 Compared to the Nine Months Ended February 28, 2011

<i>(in millions, except percentages)</i>	Nine Months Ended February 29, 2012	Percentage of Net Sales	Nine Months Ended February 28, 2011	Percentage of Net Sales	Percentage Increase/ (Decrease)
Net sales	\$ 2,098.6	100%	\$ 2,017.0	100%	4%
Cost of sales	669.9	32	609.6	30	10
Gross profit	1,428.7	68	1,407.4	70	2
Selling, general and administrative expense	800.9	38	765.4	38	5
Research and development expense	93.2	4	88.3	4	6
Amortization	250.0	12	283.3	14	(12)
Operating income	284.6	14	270.4	13	5
Interest expense	363.4	17	373.7	19	(3)
Other (income) expense	9.3		(8.7)		(207)
Other expense, net	372.7	18	365.0	19	2
Loss before income taxes	(88.1)	(4)	(94.6)	(5)	(7)
Benefit from income taxes	(18.4)	(1)	(57.6)	(3)	(68)
Net loss	\$ (69.7)	(3)%	\$ (37.0)	(2)%	88%

Sales

Net sales were \$2,098.6 million for the nine months ended February 29, 2012, and \$2,017.0 million for the nine months ended February 28, 2011. The following tables provide net sales by geography and product category:

Geography Sales Summary

<i>(in millions, except percentages)</i>	Nine Months Ended February 29, 2012	Percentage of Net Sales	Nine Months Ended February 28, 2011	Percentage of Net Sales	Percentage Increase/ (Decrease)
United States	\$ 1,273.8	61%	\$ 1,247.6	62%	2%
Europe	520.3	25	499.0	25	4
International ⁽¹⁾	304.5	14	270.4	13	13
Total	\$ 2,098.6	100%	\$ 2,017.0	100%	4%

(1) International primarily includes Canada, South America, Mexico and the Asia Pacific region.

Product Category Summary

<i>(in millions, except percentages)</i>	Nine Months Ended February 29,	Percentage of Net Sales	Nine Months Ended February 28,	Percentage of Net Sales	Percentage Increase/ (Decrease)
--	-----------------------------------	----------------------------	-----------------------------------	----------------------------	---------------------------------------

Edgar Filing: BIOMET INC - Form 10-Q

	2012 ⁽¹⁾		2011 ⁽¹⁾		(Decrease)
Large Joint Reconstructive	\$ 1,259.2	60%	\$ 1,205.1	60%	4%
Sports, Extremities, Trauma (S.E.T.)	258.2	12	228.0	11	13
Spine & Bone Healing	230.1	11	247.2	12	(7)
Dental	198.5	9	195.5	10	2
Other	152.6	8	141.2	7	8
Total	\$ 2,098.6	100%	\$ 2,017.0	100%	4%

⁽¹⁾ New product categories were adopted in order to more closely represent the way we currently report sales and market products. Certain amounts have been reclassified to conform to the current presentation.

Large Joint Reconstructive

Net sales of large joint reconstructive products for the nine months ended February 29, 2012 was \$1,259.2 million, or 60% of net sales, representing a 4% increase compared to net sales of \$1,205.1 million, also 60% of net sales, during the nine months ended February 28, 2011.

Knee product sales increased 3% worldwide and decreased 1% in the United States during the nine months ended February 29, 2012, compared to the nine months ended February 28, 2011. The worldwide growth was primarily due to knee sales growth in Europe. Europe knee sales increased primarily due to increased sales of the Vanguard® Knee as well as the Orthopaedic Salvage System. The sales increase in Europe was partially offset by decreases in the U.S. due to decreases in partial knee sales. We believe partial knee sales have declined due to macroeconomic conditions impacting patients and competitive activities with partial knee product offerings in the market place the last several years.

Hip product sales increased 7% worldwide and 6% in the United States during the nine months ended February 29, 2012, compared to the nine months ended February 28, 2011. We believe the sales increase was primarily driven by the strong market acceptance of the new Arcos[®] Modular Femoral Revision System, the new Active Articulation[®] EI system and our Taperloc[®] Complete Hip Stem, which more than offset the erosion of metal-on-metal hip sales.

Sales of bone cement and other reconstructive products increased 6% worldwide and 7% in the United States during the nine months ended February 29, 2012, compared to the nine months ended February 28, 2011. Strong sales increases of StageOne[®] hip and knee cement spacer molds particularly the StageOne[®] Select modular hip spacer molds drove sales growth in the bone cement and other reconstructive product category.

S.E.T.

Worldwide net sales of S.E.T. products for the nine months ended February 29, 2012 were \$258.2 million, or 12% of net sales, representing a 13% increase compared to net sales of \$228.0 million, or 11% of net sales, during the nine months ended February 28, 2011.

Sports medicine sales increased 18% worldwide, with an 11% sales increase in the United States, during the nine months ended February 29, 2012, compared to the nine months ended February 28, 2011. The primary contributor of sales growth in the first, second and third quarters was the JuggerKnot[®] Soft Anchor due to increased volumes from strong market acceptance.

Extremity product sales increased 17% worldwide and 19% in the United States during the nine months ended February 29, 2012, compared to the nine months ended February 28, 2011. The Comprehensive[®] Primary and Reverse Shoulder Systems continued to drive strong sales growth for the extremity product category.

Trauma product sales decreased 1% worldwide, with a 3% sales decrease in the United States, during the nine months ended February 29, 2012, compared to the nine months ended February 28, 2011. External fixation sales declined due to a continued market shift from external fixation to internal fixation products and competitive pressures, partially offset by increased internal fixation sales. The increased internal fixation sales were primarily due to strong sales of the OptiLock[®] VL Distal Radius Plating System.

Spine & Bone Healing

Worldwide net sales of spine & bone healing products for the nine months ended February 29, 2012 were \$230.1 million, or 11% of net sales, representing a 7% decrease compared to net sales of \$247.2 million, or 12% of net sales, for the nine months ended February 28, 2011. We believe the spine market continued to be affected by mid-single-digit price erosion, a slowdown in volumes due to the general economy, a challenging reimbursement environment for some fusion procedures, and a trend toward physician-owned distributorships.

Spine product sales decreased 6% worldwide and 7% in the United States during the nine months ended February 29, 2012, compared to the nine months ended February 28, 2011.

Sales of bone healing products decreased 8% worldwide and in the United States during the nine months ended February 29, 2012, compared to the nine months ended February 28, 2011.

Dental

Worldwide net sales of dental products for the nine months ended February 29, 2012 were \$198.5 million, or 9% of net sales, representing a 2% increase compared to net sales of \$195.5 million, or 10% of net sales, during the nine months ended February 28, 2011. The increased dental sales are primarily due to growth in the U.S. as a result of increased average selling prices, partially offset by decreases in the European market due to the economic uncertainty in the regions where we currently have the largest market share.

Other

Worldwide net sales of other products for the nine months ended February 29, 2012 were \$152.6 million, or 8% of net sales, representing an 8% increase compared to net sales of \$141.2 million, or 7% of net sales, during the nine months ended February 28, 2011. Our microfixation product sales grew during the first, second and third quarters both worldwide and in the United States, which were partially offset by a decrease in sales of autologous therapies.

Gross Profit

Gross profit for the nine months ended February 29, 2012 increased to \$1,428.7 million, compared to gross profit for the nine months ended February 28, 2011 of \$1,407.4 million, or 68% and 70% of net sales, respectively. Gross profit as a percentage of net sales was slightly down compared to the nine months ended February 28, 2011 due to a decrease in average selling prices, unfavorable manufacturing variances as production volumes were lower, higher instrument depreciation expense related to new product launches and costs related to the closure of the Swindon, United Kingdom plant that commenced during the second quarter of fiscal 2012.

Selling, General and Administrative Expense

Selling, general and administrative expense for the nine months ended February 29, 2012 and February 28, 2011 was \$800.9 million and \$765.4 million, respectively, or 38% of net sales for both periods. The expense increased in the nine months ended February 29, 2012 due to the costs to implement the restructuring plan commenced in the first quarter of fiscal 2012 and costs related to settlement of the FCPA investigation.

Research and Development Expense

Research and development expense during the nine months ended February 29, 2012 and February 28, 2011 was \$93.2 million and \$88.3 million, respectively, or 4% of net sales for both periods. The slight increase in research and development expenses for the nine months ended February 29, 2012 primarily related to our ongoing commitment to increase investment in clinical research and regulatory affairs within our business. Our principal research and development efforts relate to primary and revision orthopedic reconstructive devices, spinal fixation products, dental reconstructive devices, sports medicine products, resorbable technology, biomaterial products and autologous therapies.

Amortization

Amortization expense for the nine months ended February 29, 2012 was \$250.0 million or 12% of net sales, compared to \$283.3 million for the nine months ended February 28, 2011, or 14% of net sales. This decrease is primarily due to the intangible asset impairment charge taken in the fourth quarter of fiscal 2011 related to our Europe business.

Interest Expense

Interest expense was \$363.4 million for the nine months ended February 29, 2012, compared to interest expense of \$373.7 million for the nine months ended February 28, 2011. The decrease in interest expense was primarily due to a lower average interest rate on our term loan facilities as our interest rate swaps continue to mature moving more of our term loan facilities from fixed to floating rate debt.

Other (Income) Expense

Other (income) expense was expense of \$9.3 million for the nine months ended February 29, 2012, compared to income of \$8.7 million for the nine months ended February 28, 2011. The decrease is primarily due to an other-than-temporary impairment that was recorded on the Greek bonds of \$19.3 million for the nine months ended February 29, 2012.

Benefit from Income Taxes

The effective income tax rate was 20.9% for the nine months ended February 29, 2012 compared to 60.9% for the nine months ended February 28, 2011. The primary factor in determining the effective tax rate is the mix of various jurisdictions in which profits are projected to be earned and taxed. Our effective income tax rate for the nine months ended February 29, 2012 is lower than the effective income tax rate for the nine months ended February 28, 2011 primarily due to the tax impact of projected income inclusions related to U.S. anti-deferral provisions as well as updated assertions regarding the expected repatriation of earnings of our foreign operations. Fluctuations in effective tax rates between comparable periods also reflect the discrete tax benefit or expense of items in continuing operations that represent tax effects not attributable to current-year ordinary income. The tax benefit for the nine months ended February 29, 2012 was increased due to discrete items, consisting primarily of the tax benefit associated with the reduction of net deferred tax liabilities due to the prospective reduction of corporate tax rates in Japan and the United Kingdom as well as restructuring-related adjustments and finalization of the 2010 income tax returns. The tax benefit for the nine months ended February 28, 2011 was increased due to effective settlement of uncertain tax positions and the discrete impact of the reduction of corporate tax rates in the United Kingdom and was decreased due to the settlement of an IRS audit and finalization of the 2009 income tax returns.

Liquidity and Capital Resources

Cash Flows

The following is a summary of the cash flows by activity for the nine months ended February 29, 2012 and February 28, 2011:

<i>(in millions)</i>	Nine Months Ended February 29, 2012	Nine Months Ended February 28, 2011
Net cash from (used in):		
Operating activities	\$ 291.3	\$ 303.2
Investing activities	(81.7)	(175.8)
Financing activities	(28.9)	(39.6)
Effect of exchange rate changes on cash	(12.5)	10.8
Change in cash and cash equivalents	\$ 168.2	\$ 98.6

For the Nine Months Ended February 29, 2012 Compared to the Nine Months Ended February 28, 2011

Our cash and cash equivalents were \$496.0 million as of February 29, 2012 compared to \$287.7 million as of February 28, 2011. We generally maintain our cash and cash equivalents and investments in money market funds, corporate bonds and debt instruments. Cash and cash equivalents held outside of the United States were \$278.2 million as of February 29, 2012. If we were to repatriate this cash back to the United States, additional tax of up to 35%, the maximum federal tax rate, could be incurred. In addition, we require a certain amount of cash to support on-going operations outside the United States. As of February 29, 2012, we have accumulated losses at our foreign subsidiaries, primarily due to the goodwill and other intangible impairment charges that were recorded in fiscal 2011 and 2009. No cash can be repatriated so long as we continue to accumulate losses at our foreign subsidiaries. Our foreign subsidiaries have continued, however, to generate positive cash flows from operations in amounts more than sufficient to meet their debt service obligations without using cash from our U.S. operations.

Operating Cash Flows

Net cash provided by operating activities was \$291.3 million for the nine months ended February 29, 2012, compared to net cash flows provided of \$303.2 million for the nine months ended February 28, 2011. Cash generated by operating activities continued to be a source of funds for deleveraging and investing in our growth. The decrease in cash provided by operating activities of \$11.9 million was primarily due to an increase in cash paid for taxes due to net operating losses being fully utilized in the United States and an increase in accounts receivable due to increased sales with an increase in days sales outstanding.

Investing Cash Flows

Net cash used in investing activities was \$81.7 million for the nine months ended February 29, 2012 and \$175.8 million for the nine months ended February 28, 2011. The investing cash flow decrease period-over-period when comparing the nine months ended February 29, 2012 to February 28, 2011 was primarily due to the receipt of proceeds from the sale of the manufacturing facility in Parsippany which is part of the \$13.7 million of proceeds from the sale of property and equipment and the sales/maturities of investments of \$42.0 million, which was due to the sale of a time deposit in the first quarter of fiscal 2012 and receipt of the first tranche of the Greece Bonds, as compared to only \$14.6 million during the nine months ended February 28, 2011 and the decrease in capital expenditures which were \$122.7 million for the nine months ended February 29, 2012 as compared to \$133.9 million for the nine months ended February 28, 2011.

Financing Cash Flows

Net cash used in financing activities was \$28.9 million for the nine months ended February 29, 2012, compared to \$39.6 million for the nine months ended February 28, 2011. Net cash used in financing activities for the nine months ended February 29, 2012 primarily related to required payments under the senior secured credit facilities of \$26.6 million. Net cash used in financing activities for the nine months ended February 28, 2011 primarily related to required payments under the senior secured credit facilities of \$25.9 million, repurchases of senior notes of \$11.2 million and payments under European facilities of \$1.5 million.

Balance Sheet Metrics

Edgar Filing: BIOMET INC - Form 10-Q

Cash flows from operations are impacted by profitability and changes in operating working capital. Management monitors operating working capital with particular focus on certain metrics, including days sales outstanding (DSO) and inventory turns. The following is a summary of our DSO and inventory turns.

	February 29, 2012	May 31, 2011
Days Sales Outstanding ⁽¹⁾	65.3	61.3
Inventory Turns ⁽²⁾	1.57	1.54

(1) DSO is calculated quarterly by dividing the quarterly net accounts receivable balance by the quarterly net sales amount and multiplying by 91.25 days (365 days/4).

(2) Inventory turns are calculated by dividing the last twelve months cost of sales by the year-over-year average net inventory balance. We use DSO as a measure that places emphasis on how quickly we collect our accounts receivable balances from customers. Our higher DSO is the result of a global slowdown in customer payments, specifically in Europe. We are unable to continue factoring receivables in Spain which is causing our DSO to increase. We use inventory turns as a measure that places emphasis on how efficiently we are managing our inventory levels. These measures may not be computed the same as similarly titled measures used by other companies.

Non-GAAP Disclosures

We use certain non-GAAP financial measures to evaluate our performance using information that differs from what is required under GAAP. These non-GAAP financial measures may not be comparable to similar measures reported by other companies and should be considered in addition to, and not as a substitute for, or superior to, other measures prepared in accordance with GAAP.

The senior secured leverage ratio provides a measure of our financial ability to meet our debt service obligations. The ratio level determines the interest rate charged on our asset-based revolving credit facility, cash flow revolving credit facilities, and letters of credit fees. In addition to determining the current interest rate on our revolving credit facilities, the ratio is also used as a benchmark in our credit agreements to determine maximum levels of additional indebtedness we may incur. We believe the directional trend of this ratio provides valuable insight to understanding our operational performance and financial position with respect to our debt obligations.

<i>(in millions, except ratios)</i>	February 29, 2012	May 31, 2011
USD Term Loan B	\$ 2,240.6	\$ 2,258.1
EUR Term Loan B	1,125.4	1,206.3
Consolidated Senior Secured Debt	3,366.0	3,464.4
Cash and Cash Equivalents ⁽³⁾	496.0	360.9
Consolidated Senior Secured Debt Net of Cash and Cash Equivalents ⁽³⁾	\$ 2,870.0	\$ 3,103.5
LTM Adjusted EBITDA	\$ 1,014.3 ⁽²⁾	\$ 1,010.4
Senior Secured Leverage Ratio ⁽¹⁾	2.83	3.07

(1) Our senior secured leverage ratio is defined by our credit agreement as total consolidated senior secured debt net of cash and cash equivalents, as defined by our credit agreement, divided by the total of the last twelve months, or LTM, Adjusted EBITDA.

(2) The LTM Adjusted EBITDA for February 29, 2012 includes nine months of Adjusted EBITDA during fiscal year 2012 of \$753.4 million, plus the last three months of Adjusted EBITDA from fiscal year 2011 of \$260.9 million.

(3) Cash and cash equivalents as defined by the credit agreement includes \$33.1 million of time deposits at May 31, 2011.

The decrease in the senior secured leverage ratio at February 29, 2012 as compared to May 31, 2011 is primarily due to the weakening of the euro against the U.S. dollar and debt service payments, as our Adjusted EBITDA was relatively consistent for both periods presented.

Edgar Filing: BIOMET INC - Form 10-Q

We use Adjusted EBITDA, among other measures, to evaluate the performance of our core operations, establish operational goals and forecasts that are used in allocating resources and to evaluate our performance period-over-period, including for incentive program purposes. The term "as adjusted," a non-GAAP financial measure, refers to financial performance measures that exclude certain income statement line items, such as interest, taxes, depreciation or amortization, other (income) expense and/or exclude certain expenses as defined by our credit agreement, such as restructuring charges, non-cash impairment charges, integration and facilities opening costs or other business optimization expenses, new systems design and implementation costs, certain start-up costs and costs related to consolidation of facilities, certain non-cash charges, advisory fees paid to the private equity owners, certain severance charges, purchase accounting costs, stock-based compensation, litigation costs, and other related charges.

Adjusted EBITDA for the three and nine months ended February 29, 2012 and February 28, 2011, the three months ended May 31, 2011 and the year ended May 31, 2011 is calculated as follows:

<i>(in millions)</i>	Three Months Ended February 29, 2012	Three Months Ended February 28, 2011	Three Months Ended February 29, 2012	Three Months Ended February 28, 2011	Three Months Ended⁽¹⁾ May 31, 2011	Year Ended May 31, 2011
Net loss	\$ (16.5)	\$ (11.6)	\$ (69.7)	\$ (37.0)	\$ (812.8)	\$ (849.8)
Depreciation	43.9	48.0	138.0	134.2	46.9	181.1
Amortization	82.6	93.3	250.0	283.3	84.6	367.9
Interest expense	117.2	124.0	363.4	373.7	125.2	498.9
Other (income) expense	(2.8)	(3.0)	9.3	(8.7)	(2.5)	(11.2)
Income taxes	10.2	(14.5)	(18.4)	(57.6)	(157.2)	(214.8)
Special items adjustments:						
Stock-based compensation expense ⁽²⁾	3.5	5.2	12.2	14.6	(1.9)	12.7
Litigation settlements and reserves and other legal fees ⁽³⁾	12.8	2.3	21.3	9.7	2.8	12.5
Operational restructuring and consulting expenses related to operational initiatives (severance, building impairments, abnormal manufacturing variances and other related costs) ⁽⁴⁾	6.9	12.0	39.8	29.7	31.9	61.6
Sponsor fee ⁽⁵⁾	2.7	2.7	7.5	7.6	2.5	10.1
Goodwill and intangible assets impairment charge ⁽⁶⁾					941.4	941.4
EBITDA, as adjusted⁽⁷⁾	\$ 260.5	\$ 258.4	\$ 753.4	\$ 749.5	\$ 260.9	\$ 1,010.4

- (1) The three months ended May 31, 2011 shows the activity from March 1, 2011 to May 31, 2011.
- (2) Stock-based compensation expense is excluded from non-GAAP financial measures primarily because it is a non-cash expense. We believe that excluding this item is useful to investors in that it facilitates comparisons to competitors' operating results.
- (3) We exclude certain litigation-related expenses from non-GAAP financial measures that are not reflective of our ongoing operational performance. We believe this information is useful to investors in that it provides period-over-period comparability.
- (4) Restructuring charges relate principally to employee severance and facility consolidation costs resulting from the closure of facilities and other workforce reductions attributable to our efforts to reduce costs. Operational restructuring charges also include abnormal manufacturing variances related to temporary redundant overhead costs within our plant network as we continue to rationalize and move production to our larger operating locations in order to increase manufacturing efficiency. We exclude these costs from non-GAAP financial measures primarily because they are not reflective of the ongoing operating results and they are not used by management to assess ongoing operational performance. We believe the exclusion of this information in the applicable non-GAAP financial measure is useful to investors in that it provides period-over-period comparability.
- (5) Upon completion of the Merger, we entered into a management services agreement with certain affiliates of the Sponsors, pursuant to which such affiliates of the Sponsors or their successors, assigns, affiliates, officers, employees, and/or representatives and third parties (collectively, the "Managers") provide management, advisory, and consulting services to us. Pursuant to such agreement, the Managers received a transaction fee equal to 1% of total enterprise value of the Transactions for the services rendered by such entities related to the Transactions upon entering into the agreement, and the Sponsors receive an annual monitoring fee equal to 1% of our annual Adjusted EBITDA (as defined by our credit agreement) as compensation for the services rendered and reimbursement for out-of-pocket expenses incurred by the Managers in connection with the agreement and the Transactions. We exclude these costs from non-GAAP financial measures primarily because they are not reflective of the ongoing operating results and they are not used by management to assess ongoing operational performance.
- (6)

Edgar Filing: BIOMET INC - Form 10-Q

During fiscal 2011, we recorded a \$941.4 million goodwill and definite and indefinite-lived intangible asset impairment charge primarily associated with our Europe reporting unit. We exclude this non-cash charge from non-GAAP financial measures because it is not reflective of our ongoing operational performance or liquidity. We believe the exclusion of this information in the applicable non-GAAP financial measure is useful to investors in that it provides period-over-period comparability.

(7) As defined in our credit agreement.

Adjusted EBITDA growth has historically generally been in line with the growth in net sales. The fall through from net sales to Adjusted EBITDA has slowed due to a decline in gross margin percentage.

Other Liquidity Information

We have issued notes, entered into senior secured credit facilities, including term loan facilities and a cash flow revolving credit facility, and an asset-based revolving credit facility, all in connection with the Merger, all of which are primarily classified as long-term obligations. There were no borrowings under our cash flow and asset-based revolving credit facilities as of February 29, 2012. Our term loan facilities require payments each year in an amount equal to 1% of the original principal in equal calendar quarterly installments for the first seven years and three months. As of February 29, 2012, required principal payments of \$35.2 million are due within the next twelve months related to our senior secured term loan facilities.

Our revolving borrowing base available under all debt facilities at February 29, 2012 was \$713.9 million, which is net of the remaining \$22.3 million commitment of the subsidiaries of Lehman Brothers Holding Inc. and borrowing base limitations relating to the asset-based revolving credit facility.

We believe that our cash, other liquid assets and operating cash flow, together with available borrowings and potential access to credit and capital markets, will be sufficient to meet our operating expenses, research and development costs, capital expenditures and to service our debt requirements as they become due. However, our ongoing ability to meet our substantial debt service and other obligations will be dependent upon our future performance, which will be subject to business, financial, economic, regulatory and other factors. We will not be able to control many of these factors, such as economic conditions and regulatory changes in the markets where we operate and pressure from competitors. We cannot be certain that our cash flow will be sufficient to allow us to pay principal and interest on our debt, support our operations and meet our other obligations. If we do not have sufficient liquidity, we may be required to refinance all or part of our existing debt, sell assets or borrow more money. We cannot guarantee that we will be able to do so on terms acceptable to us, if at all. In addition, the terms of existing or future debt agreements may restrict us from pursuing any of these alternatives.

Off-Balance Sheet Arrangements

We do not currently have any off-balance sheet arrangements that have or are reasonably likely to have a material current or future effect on our financial condition, results of operations, liquidity, capital expenditures or capital resources.

Critical Accounting Policies and Estimates

Management's Discussion and Analysis of Financial Condition and Results of Operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In management's opinion, our critical accounting policies include revenue recognition, excess and obsolete inventory, goodwill and intangible assets, legal proceedings and other loss contingencies, and income taxes. For further information, including our significant accounting policies, refer to the audited consolidated financial statements and notes thereto included in Biomet's 2011 Form 10-K and LVB's Form 10/A. There have been no significant modifications to the policies related to our critical accounting estimates since May 31, 2011 except those listed below.

We operate in one reportable segment and evaluate goodwill for impairment at the reporting unit level. Effective September 1, 2011, in connection with our global reorganization, we made changes to our reporting unit structure. The reorganization eliminated three reporting units (U.S. Orthopedics, Sports Medicine and Biologics) and established a new reporting unit (U.S. Reconstructive). We formerly had eight, and now have six, identified reporting units for the purpose of testing goodwill for impairment. The reporting units are based on our current administrative organizational structure and the availability of discrete financial information.

We perform our annual assessment for impairment as of March 31 for all reporting units and test these balances more frequently if indicators are present or changes in circumstances suggest that impairment may exist. The estimates and assumptions underlying the fair value calculations used in our annual impairment test are uncertain by their nature and can vary significantly from actual results. Factors that management must estimate include, but are not limited to, industry and market conditions, sales volume and pricing, raw material costs, capital expenditures, working capital changes, cost of capital, and tax rates. These factors are especially difficult to predict when global financial markets are volatile. The estimates and assumptions used in our impairment tests are consistent with those we use in our internal planning. These estimates and assumptions may change from period to period. If we use different estimates and assumptions in the future, impairment charges may occur and could be material.

As of February 29, 2012, we concluded that certain indicators were present that suggested impairment may exist for our Dental Reconstructive reporting unit's goodwill and intangibles. The Dental Reconstructive reporting unit had goodwill of \$433.3 million and intangibles of \$458.6 million at February 29, 2012. The indicators of potential impairment in our Dental Reconstructive reporting unit include evidence of declining industry market growth rates in certain European and Asia Pacific markets and unfavorable margin trends resulting from change in product mix.

The impact of these recent items resulted in management initiating a preliminary step one test of goodwill and intangibles for the Dental Reconstructive reporting unit at February 29, 2012. However, the preliminary result of this interim test of impairment for the Dental Reconstructive reporting unit's goodwill and intangibles was inconclusive. We are currently completing our annual budget and strategic planning process and are continuing to evaluate overall long-term growth rates, industry information, and other valuation assumptions. We will finalize the February 29, 2012 impairment tests during our fourth quarter of fiscal 2012.

We have identified other reporting units with a material amount of goodwill that are at a higher risk of potential failure of step one of the goodwill impairment test in the future. These reporting units include the U.S. Reconstructive reporting unit (\$2,971.9 million of goodwill), the Spine and Bone Healing reporting unit (\$163.8 million of goodwill), the International reporting unit (\$569.4 million of goodwill) and the Europe reporting unit (\$241.7 million of goodwill). The level of excess fair value over carrying value for each of these higher risk reporting units is less than 10%.

Forward-Looking Statements

Management's Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with our unaudited condensed consolidated financial statements and the corresponding notes contained in this report and with the financial statements, related notes, and Management's Discussion and Analysis of Financial Condition and Results of Operation in Biomet's 2011 Form 10-K and in LVB's Form 10/A. The accompanying unaudited condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America for condensed financial information and such principles are applied on a basis consistent with the information reflected in Biomet's 2011 Form 10-K and in LVB's Form 10/A. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to the rules and regulations promulgated by the SEC. In the opinion of management, the interim financial information includes all adjustments and accruals, consisting only of normal recurring adjustments, which are necessary for a fair presentation of results for the respective interim periods.

The results of operations for the three and nine months ended February 29, 2012 are not necessarily indicative of the results to be expected for the full fiscal year ending May 31, 2012 or any future interim period. Certain statements contained in this Quarterly Report on Form 10-Q and other written and oral statements made from time to time by us do not relate strictly to historical or current facts. As such, they are considered forward-looking statements which provide current expectations or forecasts of future events. Our forward-looking statements generally relate to our growth strategies, financial results, product development, regulatory approvals, competitive strengths, the scope of our intellectual property rights, litigation, mergers and acquisitions, integration of our acquisitions, divestitures, market acceptance or continued acceptance of our products, accounting estimates, financing activities, ongoing contractual obligations, and sales efforts. Such statements can be identified by the use of terminology such as anticipate, believe, could, estimate, expect, forecast, intend, may, plan, predict, possibly, potentially, will or similar words or expressions. One must carefully consider forward-looking statements that may be affected by inaccurate assumptions, and understand that such statements involve a variety of risks and uncertainties, known and unknown, including, among others, risks related to competition in the medical device industry, reduction or interruption in our supply, quality problems and price decreases for our products and services, and international operations, as well as those discussed in the section entitled Risk Factors in Biomet's 2011 Form 10-K and in LVB's Form 10/A. Consequently, no forward-looking statement can be guaranteed and actual results may vary materially. We intend to take advantage of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 regarding our forward-looking statements, and are including this sentence for the express purpose of enabling us to use the protections of the safe harbor with respect to all forward-looking statements.

We undertake no obligation to update any forward-looking statement, but investors are advised to consult any further disclosures by us in our filings with the Securities and Exchange Commission, especially on Forms 10-K, 10-Q, and 8-K and LVB's Form 10/A, in which we may discuss in more detail various important factors that could cause actual results to differ from expected or historical results. It is not possible to foresee or identify all such factors. As such, investors should not consider any list of such factors to be an exhaustive statement of all risks, uncertainties or potentially inaccurate assumptions.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

There have been no other material changes from the information about market risk provided in Biomet's 2011 Form 10-K and in LVB's Form 10/A.

Item 4. Controls and Procedures.

Management's evaluation of disclosure controls and procedures

The Company maintains disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the Act)) and internal controls over financial reporting that are designed to provide reasonable assurance that material information required to be disclosed by the Company, including its consolidated entities, in the reports that the Company files or submits under the Act, are recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to management, including the President and Chief Executive Officer (the Principal Executive Officer) and the Chief Financial Officer (the Principal Financial Officer), as appropriate, to allow timely decisions regarding required disclosure. Prior to the filing of this report, the Company completed an evaluation under the supervision and with the participation of senior management, including the Company's Principal Executive Officer and its Principal Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures as of February 29, 2012. Based on this evaluation, the Company's Principal Executive Officer and its Principal Financial Officer concluded that Biomet and LVB's disclosure controls and procedures were effective as of February 29, 2012.

Changes in internal control over financial reporting

There were no changes in Biomet or LVB's internal control over financial reporting (as defined in Rule 13a-15(f) of the Act) during the three months ended February 29, 2012 that have materially affected, or are reasonably likely to materially affect, Biomet's internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

Information with respect to legal proceedings can be found in Note 15, Contingencies, to the unaudited condensed consolidated financial statements contained in Part I, Item 1 of this report and is hereby incorporated by reference herein. Except as discussed in these notes, there were no material developments in the legal proceedings disclosed by the Company in Part I, Item 8, Note 16 of Biomet's 2011 Form 10-K and in LVB's Form 10/A.

Item 1A. Risk Factors

As of February 29, 2012, there were no material changes in our risk factors from those disclosed in Part I, Item 1A in Biomet's 2011 Form 10-K and in LVB's Form 10/A except for items noted below.

We may record future goodwill and/or intangible impairment charges related to one or more of our business units, which could materially adversely impact our results of operations.

We test our goodwill and indefinite lived intangible asset balances as of March 31 of each fiscal year for impairment. We test these balances more frequently if indicators are present or changes in circumstances suggest that impairment may exist. In evaluating the potential for impairment we make assumptions regarding revenue projections, growth rates, cash flows, tax rates, and discount rates. These assumptions are uncertain and by nature can vary from actual results. Various future events could have a negative impact on the fair value of our reporting units goodwill and indefinite lived intangibles when the annual or interim impairment test is completed. The events include, but are not limited to:

our ability to sustain sales and earnings growth;

the effect of anticipated changes in the size, health and activities of the population or on the demand for our products;

our ability and intent to expand in key international markets;

the timing and anticipated outcome of clinical studies;

assumptions concerning anticipated product developments and emerging technologies;

our continued investment in new products and technologies;

the ultimate marketability of products currently being developed;

our success in achieving timely approval or clearance of our products with domestic and foreign regulatory entities; and

the stability of certain foreign economic markets.

As of February 29, 2012, we concluded that certain indicators were present that suggested impairment may exist for our Dental Reconstructive reporting unit's goodwill and intangibles. The Dental Reconstructive reporting unit had goodwill of \$433.3 million and intangibles of \$458.6 million at February 29, 2012. The indicators of potential impairment in our Dental Reconstructive reporting unit include: evidence of declining industry market growth rates in certain European and Asia Pacific markets and unfavorable margin trends resulting from change in product mix.

The impact of these recent items resulted in management initiating a preliminary step one test of goodwill and intangibles for the Dental Reconstructive reporting unit at February 29, 2012. However, the preliminary result of this interim test of impairment for the Dental Reconstructive reporting unit's goodwill and intangibles was inconclusive. We are currently completing our annual budget and strategic planning process and are continuing to evaluate overall long-term growth rates, industry information, and other valuation assumptions. We will finalize the February 29, 2012 impairment tests during our fourth quarter of fiscal 2012.

Certain provisions of the Dodd-Frank Wall Street Reform and Consumer Protection Act may soon require us to report on conflict minerals used in our products and the due diligence plan we put in place to track whether such minerals originate from the Democratic Republic of Congo and adjoining countries. The implementation of these requirements could affect the sourcing and availability of minerals used in certain of our products.

These risk factors could materially affect our business, financial condition or operating results. Additional risks and uncertainties not currently known to the Company or that the Company currently deems to be immaterial also may, in the future, materially adversely affect our business, financial condition or results.

We, like other companies in the orthopedic industry, are involved in ongoing governmental investigations, the results of which may adversely impact our business and results of operations.

In September 2010, we received a Civil Investigative Demand (CID) issued by the U.S. Department of Justice Civil Division pursuant to the False Claims Act. The CID requests that we provide documents and testimony related to allegations that we and OtisMed Corp. and Stryker Corp. have violated the False Claims Act relating to the marketing of, and payment submissions for, OtisMed's OtisKnee (a registered trademark of Otis Med) knee replacement system. We have produced responsive documents and are fully cooperating in the investigation. We can make no assurances as to the time or resources that will be needed to devote to this inquiry or its final outcome.

In February 2010, we received a subpoena from the Office of the Inspector General of the U.S. Department of Health and Human Services requesting various documents relating to agreements or arrangements between physicians and our Interpore Cross subsidiary for the period from 1999 through the present and the marketing and sales activities associated with Interpore Cross spinal products. We are cooperating with the request of the Office of the Inspector General. We can make no assurances as to the time or resources that will be needed to devote to this inquiry or its final outcome.

In April 2009, we received an administrative subpoena from the U.S. Attorney's Office for the District of Massachusetts requesting various documents relating primarily to the Medicare reimbursement of and certain business practices related to our EBI subsidiary's non-invasive bone growth stimulators. It is our understanding that competitors in the non-invasive bone growth stimulation market received similar subpoenas. We received subsequent subpoenas in connection with the investigation in September 2009, June 2010 and February 2011 along with several informal requests for information. We are producing responsive documents and are fully cooperating in the investigation. We can make no assurances as to the time or resources that will be needed to devote to this investigation or its final outcome.

In April 2009, we became aware of a qui tam complaint alleging violations of the federal and various state False Claims Acts filed in the United States District Court for the District of Massachusetts, where it is currently pending. Biomet, its parent company LVB Acquisition, Inc., and several of our competitors in the non-invasive bone growth stimulation market were named as defendants in this action. The allegations in the complaint are similar in nature to certain categories of requested documents in the above-referenced administrative subpoenas. The U.S. government has not intervened in the action. We are vigorously defending this matter and intend to continue to do so. We can make no assurances as to the time or resources that will be needed to devote to this investigation or its final outcome.

On September 25, 2007, we received a letter from the SEC informing us that it is conducting an informal investigation regarding possible violations of the Foreign Corrupt Practices Act, or FCPA, in the sale of medical devices in certain foreign countries by companies in the medical devices industry. The FCPA prohibits U.S. companies and their officers, directors, employees, shareholders acting on their behalf and agents from offering, promising, authorizing or making payments to foreign officials for the purpose of obtaining or retaining business abroad or otherwise obtaining favorable treatment and this law requires companies to maintain records which fairly and accurately reflect transactions and to maintain internal accounting controls. In many countries, hospitals and clinics are government-owned and healthcare professionals employed by such hospitals and clinics, with whom we regularly interact, may meet the definition of a foreign official for purposes of the FCPA. If we are found to have violated the FCPA, we may face sanctions including fines, criminal penalties, disgorgement of profits and suspension or debarment of our ability to contract with government agencies or receive export licenses. On November 9, 2007, we received a letter from the Department of Justice requesting any information provided to the SEC be provided to the Department of Justice on a voluntary basis.

On March 26, 2012, Biomet entered into a Deferred Prosecution Agreement (DPA) with the U.S. Department of Justice (DOJ) and a Consent to Final Judgment (Consent Agreement) with the SEC related to these investigations by the DOJ and the SEC. Pursuant to the DPA, the DOJ has agreed not to prosecute the Company in connection with this matter, provided that the Company satisfies its obligations under the agreement over the next three years. In addition, pursuant to the terms of the DPA, an independent external compliance monitor will be appointed to review the Company's compliance with the DPA, particularly in relation to the Company's international sales practices, for at least the first 18 months of the three year term of the DPA. The Company has also agreed to pay a monetary penalty of \$17.3 million to resolve the charges brought by the DOJ. The terms of the DPA and the associated monetary penalty reflect the Company's full cooperation throughout the investigation.

The Company has contemporaneously reached a Consent Agreement with the SEC to settle civil claims related to this matter. As part of the Consent Agreement, Biomet has agreed to the SEC's entry of a Final Judgment requiring Biomet to disgorge profits and pay prejudgment interest in the aggregate amount of \$5.6 million.

From time to time, we have been, and may be in the future, the subject of additional investigations. If, as a result of these investigations described above or any additional investigations, we are found to have violated one or more applicable laws, our business, financial condition, results of operations and cash flows could be materially adversely affected. If some of our existing business practices are challenged as unlawful, we may have to modify those practices, which could have a material adverse effect on our business, financial condition, results of operations and cash flows.

Compliance with the terms of the Corporate Integrity Agreement and the Deferred Prosecution Agreement requires cooperation by many employees and others and may divert substantial financial and human resources from our other business activities.

On September 27, 2007 we entered into a Deferred Prosecution Agreement with the U.S. Attorney's Office for the District of New Jersey. The agreement concluded the government's investigation into whether consulting agreements between the largest orthopedic manufacturers and orthopedic surgeons who use joint reconstruction and replacement products may have violated the federal Anti-Kickback Statute. Through the agreement, the U.S. Attorney's Office agreed not to prosecute Biomet, Inc. and our wholly-owned subsidiary Biomet Orthopedics, LLC in connection with this matter, provided that we satisfied our obligations under the agreement for 18 months subsequent to September 27, 2007. The agreement called for the appointment of an independent monitor to review our compliance with the agreement, particularly in relation to our consulting agreements. The independent monitor filed a final report with the U.S. Attorney's Office for the period from September 27, 2007 through March 1, 2009. On March 27, 2009, the Deferred Prosecution Agreement expired and the complaint was dismissed with prejudice.

As part of the resolution of this matter, we entered into a Corporate Integrity Agreement with the Office of the Inspector General of the U.S. Department of Health and Human Services, or OIG-HHS. The agreement requires us for five years subsequent to September 27, 2007 to continue to adhere to our Code of Business Conduct and Ethics and certain other provisions, including reporting requirements.

On March 26, 2012, Biomet entered into a DPA with the DOJ related to this investigation. Pursuant to the DPA, the DOJ has agreed not to prosecute the Company in connection with this matter, provided that the Company satisfies its obligations under the agreement over the next three years. In addition, pursuant to the terms of the DPA, an independent external compliance monitor will be appointed to review the Company's compliance with the DPA, particularly in relation to the Company's international sales practices, for at least the first 18 months of the three year term of the DPA.

We are committed to continuing to devote sufficient resources to meet our obligations under the Corporate Integrity Agreement and DPA. Compliance with these agreements requires substantial cooperation of our employees, distributors and sales agents and the healthcare professionals with whom they interact. These efforts not only involve expense, but also require management and other key employees to focus extensively on these matters.

We could be subject to further governmental investigations or actions by other third parties as a result of our settlements with the Department of Justice and OIG-HHS.

As discussed in Business Government Regulation , we are subject to various federal and state laws concerning healthcare fraud and abuse, including false claims laws and anti-kickback laws. Violations of these laws are punishable by criminal and/or civil sanctions, including, in some instances, fines, imprisonment and, within the United States, exclusion from participation in government healthcare programs, including Medicare, Medicaid and Veterans Administration (VA) health programs. These laws are administered by, among others, the U.S. Department of Justice, the Office of Inspector General of the Department of Health and Human Services and state attorneys general. Many of these agencies have increased their enforcement activities with respect to medical device manufacturers in recent years.

As discussed in Note 15, Contingencies, to the condensed consolidated financial statements contained in Part I, Item 1 of this report, on March 26, 2012, Biomet entered into a DPA with the DOJ and a Consent Agreement with the SEC related to the FCPA investigations by the DOJ and the SEC. Pursuant to the DPA, the DOJ has agreed not to prosecute the Company in connection with this matter, provided that the Company satisfies its obligations under the agreement over the next three years. In addition, pursuant to the terms of the DPA, an independent external compliance monitor will be appointed to review the Company's compliance with the DPA, particularly in relation to the Company's international sales practices, for at least the first 18 months of the three year term of the DPA. We intend to review and take appropriate actions with respect to complying with the terms of the DPA; however, we cannot assure that the costs of complying with such obligations would not have a material adverse effect on our financial condition, results of operations and cash flows or that the settlement would not prompt further governmental investigations related to the matters described in the DPA.

Item 6. Exhibits.

(a) Exhibits. See Index to Exhibits.

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, LVB Acquisition, Inc. and Biomet, Inc. have duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

LVB ACQUISITION, INC.

BIOMET, INC.

Date: April 13, 2012

By: /s/ JEFFREY R. BINDER
Jeffrey R. Binder
President and Chief Executive Officer

Date: April 13, 2012

By: /s/ DANIEL P. FLORIN
Daniel P. Florin
Senior Vice President and Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Exhibit
31.1	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification to 18 U.S.C Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101. PRE	XBRL Taxonomy Extension Presentation Linkbase Document